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A bstract
Free, unbound and therefore biologically available ionised magnesium (IMg) plays vital
roles in a variety of physiological and biochemical processes. This includes the proper
functioning of many enzyme systems and the regulation of transmembrane movements
of cations.

The cardiovascular system is highly dependent on IMg, and numerous

studies indicate that decreases in IMg concentrations are associated with a number of
cardiovascular disease states.

Coronary heart disease with myocardial infarction is a leading cause of death, with
patient survival enhanced by quick and accurate diagnosis. Quick diagnosis by the
physician and prompt therapeutic intervention (i.e. thrombolytics or invasive surgery)
can minimise damage to the heart muscle. However, in a large group of patients an
accurate diagnosis of acute myocardial infarction (AMI) cannot be made rapidly and is
only possible after biochemical testing.

The aim of this study was to determine serum IMg, total magnesium (TMg) and
Creatine Kinase-MB (CK-MB) concentrations in patients with AMI and in other
patients admitted to hospital on account of chest pain in which a diagnosis of AMI was
ruled out. The study was undertaken to evaluate any trends in IMg concentrations
associated with AMI, and to determine if IMg concentrations could be used as a
diagnostic tool for AMI. Blood samples were taken from volunteers (n = 72) with
suspected AMI on admission to hospital and at approximately 6 hour intervals, for up to
66 hours, after the onset of chest pain. A control group of non-AMI volunteers (n = 90)
(age and sex matched) was also monitored within the same time intervals.
A bstract

Xll

Measurement of serum TMg did not serve as a reliable indicator of magnesium status in
patients with AMI. Total magnesium concentrations remained constant (.P = 0.996)
throughout the monitoring period of the AMI group, despite a drop in IMg over the
same period. Statistically significant differences (P <0.001) in IMg concentrations were
found between the AMI and non-AMI groups. At the 1 8 - 2 4 hour time interval the
IMg concentration of the AMI group decreased significantly (P <0.001) by 7.0%,
returning to pre-infarction levels between 30 - 42 hours. The serum IMg concentrations
were unchanged (P = 0.276) in the non-AMI group.

Results from this study support the conclusion that it may be clinically useful to monitor
IMg in patients with AMI. From the data available, however, the low sensitivity (61%)
and specificity (71%) of IMg in predicting AMI reduced its use as a clinical diagnostic
tool for the detection of myocardial injury.

A bstract
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Chapter 1 T h e r o l e o f i o n i s e d m a g n e s i u m in
CARDIOVASCULAR FUNCTION AND
PATHOLOGY

1.1

Introduction - G eneral overview of magnesium function

Magnesium is an important biological element and an essential requirement for all
living things. It is present in all cells and is the fourth most abundant metal element in
the body and the second most abundant intracellular cation, potassium being the most
abundant (118). A common, essential dietary element and electrolyte, magnesium plays
major roles in health and disease. Magnesium is gaining increasing attention following
experimental and clinical studies on its biological roles and pharmacological influences.
Free, i.e. unbound or ionised magnesium (IMg), is the biologically active form and
plays a major role in numerous cellular processes, such as in the regulation of
transmembrane ionic fluxes, excitation-contraction coupling, and energy metabolism.

Table 1.1 lists some of the physiological functions of IMg. In the human body, IMg is
an essential cofactor for over 320 enzymes. Ionised magnesium is essential for many
physiological processes by serving as a co-factor predominantly involved in the transfer,
storage and utilisation of energy (15). It plays important roles in enzymatic reactions in
two general ways. Complexes formed from the binding of magnesium and substrate
facilitate enzyme interaction with the substrate. Alternatively, magnesium ions bind
directly to the enzyme, altering its structure and/or serving a catalytic role.
For example, by activating phosphate groups and reactions that involve adenosine
triphosphate (ATP), the cytoplasmic and mitochondrial level of IMg serves to regulate
the processes of glycolysis and Krebs cycle (9, 135).
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Table 1.1
Physiological functions of ionised magnesium.
Cofactor for
Enzyme function

Structural
Function

Membrane Function

Calcium Antagonist

7 Glycolytic Enzymes

Proteins

2+
Gating of Ca channels

Muscle contraction/relaxation

5 Krebs Cycle

Polyribosomes

Transmembrane flux of ions

Action potential conduction in

Enzymes

Nucleic acids

Adenylate cyclase system

nodal tissue

Membrane ATPases

Mitochondria

Kinases-creatine kinase
Reproduced from reference (15).

Because of its numerous biochemical cellular activities, IMg plays an important role in
control of cardiac excitability, vasomotor tone, muscular contraction, blood pressure
and peripheral blood flow. Recent work has suggested that IMg can affect myocardial
contractility and excitability by a number of cellular pathways (115). The regulation of
transmembrane ion fluxes constitutes a most important aspect of the part played by IMg
in cardiac function. Nerve and muscle cells of the heart and the vasculature require
IMg, together with potassium and calcium, to conduct electrical impulses and/or to
contract.

Ionised magnesium serves to regulate potassium concentrations by

influencing the function of sodium/potassium adenosine triphosphatase (Na+/K+ATPase) pumps, voltage-gated potassium channels and acetylcholine-gated cation
channels, which shape the cardiac action potential. Ionised magnesium is required to
regulate intracellular calcium concentration by influencing calcium-ATPase (Ca ATPase) pumps, sodium/calcium exchange systems and voltage-gated calcium
channels, which are essential for contraction of heart muscle.

Ionised magnesium
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activates adenyl cyclase and phosphodiesterase and therefore controls cyclic AMP
concentration, which in turn regulates the activity of these transport systems (115).

The heart with its dense mitochondrial structure and high enzymatic activity is
particularly vulnerable to magnesium loss.

Magnesium deficiency due to diet or

abnormalities in magnesium metabolism has been shown to play an important role in
disease states such as ischaemic heart disease (IHD) and acute myocardial infarction
(AMI), cardiac arrhythmias, hypertensive vascular disease and atherosclerosis (9, 86).
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1.2

D istribution of total and ionised magnesium in the body

Table 1.2 shows the distribution of total and ionised magnesium in the adult human.
The distribution and percentage of total and ionised magnesium varies among the
tissues of the body. Approximately 52.9% of total magnesium (TMg) is present in bone
(37), 27.0% in muscle, 19.3% is present in soft tissue, 0.5% in red blood cells, and 0.3%
in serum (50, 98). The distribution of EMg shows 54.6% in muscle, 38.2% in soft
tissue, 1.4% in red blood cells, and 5.8% in serum (50). From values seen in different
studies, the mean TMg concentrations have been found to range from 0.75 - 1.50
mmol/L in serum, 2.3 - 2.7 mmol/kg in red blood cells, 8.3 - 8.7 mmol/kg in soft tissue,
8.8 - 9.2 mmol/kg in muscle and 42.9 - 43.5 mmol/kg in bone (50, 80, 98). From these
studies, serum IMg concentrations have been found to range from 0.50 - 0.65 mmol/L
(used in subsequent chapters). This agrees with the values established in this study of
0.56 ± 0.05 mmol/L (from 100 normal, healthy individuals).

Furthermore, IMg

concentrations have been reported to range from 0.19 - 0.23 mmol/kg in red blood cells,
0.48 - 0.52 mmol/kg in soft tissue and 0.52 - 0.56 mmol/kg in muscle (12, 50, 84, 88,
105).
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Table 1.2
Distribution of total and ionised magnesium in the adult human.
Concentration
(mmol/kg wet weight)

Content
(mmol)

Tissue

Body Magnesium
(%)

Total
(mean)

Ionised
(mean)

Total

Ionised

%
Ionised

Total

Ionised

Serum

0.75-1.50
(1.1)

0.50 - 0.65
(0.58)

2.6

1.71

67.1

0.3

5.8

Red Blood
Cells

2.3 - 2.7
(2.5)

0.19-0.23
(0.21)

5.0

0.42

8.4

0.5

1.4

Soft Tissue

8.3 - 8.7
(8.5)

0.48 - 0.52
(0.50)

193.0

11.35

5.9

19.3

38.2

Muscle

8.8 - 9.2
(9.0)

0.52-0.56
(0.54)

270.0

16.20

6.0

27.0

54.6

Bone

42.9-43.5
(43.2)

-

530.1

-

52.9

-

Adapted from references (12, 50, 80).

In most tissues magnesium is normally found in three states, approximately 33% is
bound to plasma proteins (predominantly albumin), approximately 12% is complexed to
small anions (e.g. bicarbonate, phosphate, or sulphate), and 55% in ‘free’, biologically
active, ionised form (98). These three fractions, routinely measured as TMg, are in an
equilibrium that can be altered by in vivo processes. As with other blood electrolytes,
the physiological action of magnesium is related only to the activity of IMg.
Because changes in IMg concentration are not necessarily reflected as changes in TMg
concentration (17, 24, 91, 98), direct measurement of EMg may be clinically more useful
than measurement of TMg (50).
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1.2.1

Absorption and Excretion of Magnesium

Approximately 35 - 40% of the ingested magnesium is absorbed via the jejunum and
ileum (6, 82). Under normal physiological conditions, the kidney is the prime regulator
of magnesium balance in the body. Approximately 5% - 10% of the filtered load is
excreted by the kidneys (120). About 25 % of the filtered magnesium is reabsorbed in
the proximal tubule and approximately 60% in the loop of Henle, by mechanisms still
unknown (15). Consequently, malfunctioning kidneys are one of the most frequent
causes of magnesium abnormality. Table 1.3 summarises several physiological and
pharmacological factors that influence renal handling of magnesium.

Table 1.3
Physiological and pharmacological factors influencing renal
handling of magnesium.

Factors stimulating Mg2+reabsorption

Factors inhibiting Mg2+reabsorption

Low plasma Magnesium

High plasma Magnesium

Low plasma Calcium

High plasma Calcium

Parathyroid Hormone

Salt, osmotic diuresis (Alcohol, Loop diuretics, etc)

Calcitonin

Gentamicin

Antidiuretic Hormone

Cyclosporine

Reproduced from reference (15).
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1.2.1.1

Magnesium deficiency

Several clinical and experimental trials, which are discussed below (Sections 1.5.1,
1.5.2, 1.5.3 and 1.5.4), have shown that magnesium deficiency, rather than excess, leads
to various cardiovascular disease states (33). Table 1.4 lists some causes of clinical
hypomagnesaemia. Potential causes of low serum and tissue magnesium concentrations
include excessive gastrointestinal losses, renal losses, and endocrine disorders.
Gastrointestinal factors include alcoholism, diarrhoea, and malabsorption. Renal losses
of magnesium are associated with acute renal failure, hyperthyroidism and in some
circumstances are drug induced. Diuretic, cyclosporine, and antibiotic (e.g. Gentamicin
and Ticarcillin) therapy have been associated with cases of severe hypomagnesaemia
(116).

Digoxin, a drug often prescribed to control cardiac arrhythmias, promotes

magnesium depletion by inhibiting renal tubular reabsorption of magnesium, resulting
in increased urinary excretion (24). Endocrine disorders with renal loss of magnesium
include diabetic ketoacidosis, hyperparathyroidism, and hyperaldosteronism. Excessive
lactation, exchange transfusions, and acute intermittent porphyria can also cause
excessive magnesium loss (98, 126).
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Table 1.4
Causes of clinical hypomagnesaemia

Category
Gastrointestinal

Causes of clinical hypomagnesaemia
Alcoholism
Diarrhoea
Short bowel syndrome
Malabsorption
Acute and recurrent pancreatitis

Renal

Diuretics
Antibiotics (ticarcillin, gentamicin, carbenicillin)
Cisplatin
Cyclosporine
Hypercalcaemic states (including malignancies)
Acute tubular necrosis (diuretic phase)
Aldosteronism

Endocrine

Diabetic ketoacidosis
Hyperparathyroidism
Hyperthyroidism
Hyperaldosteronism

Miscellaneous

Excessive lactation
Exchange transfusion
Acute intermittent porphyria

Reproduced from references (57, 151).

A striking finding reported by a number of authors is that a magnesium-deficient state
may coexist with normal serum TMg (24, 91, 98).

Recent studies have shown

significant depression (20% to 45%) of serum IMg concentrations in patients with a
variety of coronary heart diseases and myocardial ischaemic syndromes (e.g. unstable
angina pectoris, sudden death ischaemic heart disease, and cardiomyopathies), despite
normal TMg levels (45, 82, 100, 151). Several distinctions have been made between
IMg and TMg concentrations, which may help to explain these inconsistencies. Total
magnesium is more stable than IMg and essentially independent of the equilibrium. It is
an indirect assessment of magnesium status, since it includes all the inactive fractions.
Chapter 1 - The role of ionised magnesium in cardiovascular function
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On the other hand, IMg concentrations fluctuate depending upon physiological
conditions and therefore are a direct indicator of magnesium status (50).

1.3

Transport of ionised magnesium across cell membranes

The above-mentioned diverse functions of magnesium are mediated in part via changes in
intracellular IMg concentrations. The mechanisms involved in IMg transport across the
membrane of myocardial cells remain obscure. Several authors report that IMg influx
may occur via a specific magnesium channel, or through other channels, such as the slow
calcium channels (61, 152). However, this has yet to be proven. Similarly, the outward
movement of IMg through the myocardial cell membrane is a matter of dispute. The lipid
bilayer of the cell membrane is highly impermeable to charged molecules (ions) and
therefore IMg cannot simply diffuse into the cell (7). Several authors have reported the
presence of sodium/magnesium (Na+/Mg2+) antiport systems.

A Na+/Mg2+ antiport

system is a membrane transport carrier protein that functions by transferring magnesium
ions across the lipid bilayer of a membrane by simultaneously transferring sodium ions in
the opposite direction (31, 55, 102). For example, the Na+/Mg2+ antiporter has been
observed to exchange one magnesium ion (out of the cell) for three sodium ions (into the
cell) (56, 63, 93, 101, 117). Figure 1.1 is a schematic diagram showing the Na+/Mg2+
carrier protein functioning as an antiport system.
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Figure 1.1
Na /Mg

carrier protein functioning as an antiporter

Reproduced from reference (7).

C h a p t e r 1 - T h e r o l e o f io n is e d
AND PATHOLOGY

m a g n e s iu m in c a r d io v a s c u l a r f u n c t io n

Page 1

1.4

T he role of ionised magnesium in cellular processes and
CARDIOVASCULAR FUNCTION

1.4.1

Ionised Magnesium and Adenosine Triphosphate

ATP is present in all cells of living organisms. Most of the processes accompanied by
changes in free energy that take place in living organisms are due to the synthesis or
breakdown of ATP. Within cells, all enzymatic reactions that involve ATP show an
absolute requirement for IMg. Adenosine triphosphate forms a complex with IMg,
magnesium-ATP (Mg2+-ATP), with magnesium binding to the phosphate moiety.
Figure 1.2 shows the structure of the Mg2+-ATP complex. Magnesium has a single
divalent state and does not form highly stable chelates with organic complexes. It is this
quality that allows IMg to act as a bridge in a large number of chemical reactions,
resulting in the transfer of organic groups from one molecule to another (25).

Figure 1.2
The structure of the Mg2+-ATP complex.
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The importance of IMg in cellular metabolism is nowhere more obvious than in
glycolysis (Figure 1.3). Glycolysis is the process by which glucose molecules are
enzymatically degraded in a sequence of ten enzyme-catalyzed reactions to yield ATP
and pyruvate. The substrate binding sites of many of the glycolytic enzymes appear
specific for the magnesium complexes of the phosphorylated intermediates. Ionised
magnesium forms complexes with phosphate groups of the glycolytic intermediates and
of adenosine diphosphate (ADP) and ATP. For example, in the first step the glucose
molecule is primed for subsequent reactions to yield glucose 6-phosphate at the expense
of ATP. This reaction is catalysed by hexokinase, which requires IMg because the true
substrate of the enzyme is not ATP but the Mg2+-ATP complex (32).
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Figure 1.3
Glycolytic cycle illustrating the general importance of the magnesium cofactor.
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Inside the mitochondria, the Krebs cycle acts as the final common pathway for the
oxidation of carbohydrates, lipids and proteins (Figure 1.4). Ionised magnesium is an
important component of the decarboxylation reaction and several of the essential
enzymes in this pathway are magnesium-dependent (27).

Figure 1.4
Krebs cycle illustrating the general importance of magnesium.
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Furthermore, IMg is necessary for oxidative phosphorylation of ADP and adenosine
monophosphate (AMP).

Within the mitochondria, the energy rich molecules of

nicotinamide adenine dinucleotide (NAD) and flavin adenine dinucleotide (FAD)
formed from glycolysis, Krebs cycle etc, generate the high-energy intermediate ATP
(Oxidative Phosphorylation).

They are oxidised by the cytochrome system, where

electron migration between NAD and FAD, and the cytochromes is stimulated by
magnesium, to form ATP (27).

Moreover, IMg serves to regulate the energy source (ATP) available for muscular
contraction. When muscle contracts, ATP is consumed to form ADP. Creatine kinase
catalyses the rephosphorylation of ADP to form ATP. Heart and skeletal muscle also
store high-energy phosphates temporarily in the form of creatine phosphate. Creatine
phosphate acts as a backup store for rapid regeneration of ATP when levels fall because
of increased demand. Figure 1.5 illustrates how creatine kinase catalyses the reversible
transfer of a phosphoryl group from creatine phosphate to ADP to form ATP.
Ionised magnesium plays an essential regulatory role in the way creatine kinase
(creatine kinase -

MB fraction (CK-MB) in the heart muscle) functions.

Aukawa (25) reported that with low physiological magnesium concentration creatine
phosphate is preferentially synthesised, while high physiological magnesium
concentration preferentially generate ATP.

Therefore, the EMg concentration

effectively serves to regulate the rates of forward and reverse reactions, keeping the
concentration of ATP constant.
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Figure 1.5
Creatine phosphate transfer o f phosphate group to ADP to form ATP.
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1.4.2

Effect of Ionised Magnesium on Ion Channels

1.4.2.1

Ionised magnesium regulates the cardiac action potential

The electrical activity of the myocardial cell and the specialised electrical conduction
system of the heart are derived from the ability of the cell to alter the electro-chemical
gradient across the cell membrane, or sarcolemma (115). Most animal cells have a high
intracellular concentration of potassium (K+) and a low intracellular concentration of
sodium (Na+) relative to the external medium.

Transmembrane movement of ions

(primarily sodium, potassium and calcium) sequentially depolarise and repolarise the
cell membrane resulting in an action potential. The active transport of sodium and
potassium is therefore of great physiological significance. More than a third of the ATP
consumed is used to pump these ions across the cell membrane (7).

Figure 1.6 is a schematic representation of three different Na+/K+ channels and pumps
that are regulated by IMg.

The Na+/K+ ATPase pump (Fig. 1.6A) operates as an

antiporter, actively pumping sodium out of the cell against its steep electrochemical
gradient and pumping in potassium (7). This enzyme is dependent on IMg as a cofactor
and derives its energy from hydrolysis of Mg2+-ATP. Each ATPase contains a catalytic
subunit, which is sequentially phosphorylated and dephosphorylated during the
pumping cycle (7). Consequently, IMg helps to maintain the transmembrane gradients
of sodium and potassium that determine the electric potential across the cellular
membrane.

Mclean et al (98) reports that deficiency in magnesium may result in

neuromuscular excitability and irritability as alterations in sodium/potassium gradients
and transmembrane potential occur.
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Figure 1.6
Ionised magnesium’s role in three different ion channels and pumps.

Cation Channels
Reproduced from references (5,7).

Similarly, voltage-gated potassium channels (Fig. 1.6B) and acetylcholine-gated
potassium channels (Fig. 1.6C) are also responsible for the maintenance of the resting
potential and generating the plateau of the action potential in the plasma membrane of
all electrically excitable cells (e.g. muscle, neurons and endocrine cells) (5).
Voltage-gated potassium channels open so that the transient influx of sodium is rapidly
overwhelmed by an efflux of potassium, driving the membrane back toward the
potassium equilibrium potential. Acetylcholine-gated potassium channels are opened
by acetylcholine binding to receptors on the myocyte plasma membrane.
Unlike voltage-gated potassium channels, acetylcholine-gated cation channels have
little selectivity among cations and so the normal traffic consists of sodium, potassium
and some calcium.

Ionised magnesium regulates the activity of these channels by
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blocking the opening when the cell becomes polarised - depolarisation removes
magnesium and the channels open (5, 68, 96). Matsuda and co-workers have shown
that when magnesium concentrations are reduced, the inward rectifying properties of the
potassium channels are lost (96).

Similarly, in mammalian atrial and ventricular

myocytes, Agus et al (5) report that in the absence of intracellular magnesium, the
current/voltage relationship of these channels is virtually linear. In other words, when
intracellular magnesium is reduced to zero, potassium ions are carried equally in both
directions across the membrane.

Losses of cytoplasmic magnesium together with

potassium efflux are two of the earliest signs of ischaemic injury (5).

1.4.2.2

Ionised magnesium regulates myocardial contractility

Ionised magnesium serves to regulate intracellular calcium concentrations and therefore
regulate myocardial contractility.

Three possibilities have been reported for the

regulation of calcium; they are the calcium ATPase (Ca -ATPase) pumps,
sodium/calcium (Na+/Ca2+) antiport systems (74, 123) and voltage-gated calcium
channels.

Entry of calcium into heart muscle cells, however small, is believed to help trigger
release of calcium stored in the sarcoplasmic reticulum, which in turn initiates muscle
contraction (99, 117). Calcium ions are pumped out from the sarcoplasmic reticulum
through membrane bound Ca2+-ATPase pumps, flooding the cytosol and initiating the
contraction of each myofibril. The increase in calcium concentration in the cytosol is
transient because calcium is pumped back into the sarcoplasmic reticulum by the
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reverse action of Ca2+-ATPase (64, 83, 123). Restoration of the cytosolic calcium
concentration causes the myofibrils to relax. The activity of Ca2+-ATPase derives its
energy from hydrolysis of Mg2+-ATP. Magnesium thus serves to regulate calcium
handling by the sarcoplasmic reticulum (74). Furthermore, after a contraction, excess
calcium has been reported to be removed from the cell by Na+/Ca2+ antiport systems
(Fig. 1.1 above is an example of an antiporter) (123). Calcium efflux is compensated by
the entry of three sodium ions into the cell through the Na+/Ca2+ antiport system.
Mg2+-ATP provides the energy necessary for this exchange (123).

Ionised magnesium has also been found to regulate calcium influx into the myocyte
through sarcolemmal voltage-gated calcium channels (115).

Voltage-gated calcium

currents play a major role in the development of the cardiac action potential, in the
generation of electrical pacemaking in nodal tissue, and in the initiation of muscle
contraction. When the cell becomes polarised, intracellular IMg has a blocking effect
on the calcium current - depolarisation removes magnesium and the channels open.
(24). The role that IMg serves by regulating voltage-gated calcium currents can explain
some of the pathological effects of magnesium deficiency in the heart. When normal
processes that maintain low intracellular calcium concentrations are interrupted
(for example, during ischaemia), increases in voltage-gated calcium currents produced
by loss of intracellular IMg may contribute to calcium overload and myocardial damage
(123).
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Ionised magnesium also affects myocardial contractility by modulating the second
messenger system, adenylate cyclase-cyclic AMP (cAMP) (136). Membrane-bound
ATPases as well as the slow calcium channels of the heart, are stimulated by cAMP
(136). The formation of cAMP from ATP is catalysed by a plasma membrane-bound
enzyme, adenylate cyclase.

Cyclic AMP is rapidly and continuously destroyed by

phosphodiesterases present in the cell.

Elevation of cAMP produces a very large

increase in the number of opened ATPase and slow channels available (136).
Therefore, any agents that increase the cAMP level of the myocardial cell will initiate
calcium influx and contraction (115).

Hence, increase and decrease in cAMP

concentrations participate in coronary vasodilatation and constriction, respectively (13).
Ionised magnesium has been shown to activate both adenylate cyclase and
phosphodiesterase activity and therefore controls cAMP production (13, 98).

Altogether, a 10,000-fold intracellular to extracellular calcium gradient is created and
maintained by these pumps and channels, which is crucial to muscle contraction (134).
In a simplified model, Iseri et al (74) reports that a reduction in magnesium would let
too much calcium into the muscle cell, thereby prolonging contraction and resulting in
abnormalities such as hypertension, neurologic deficits, ischaemia and stroke.
On the other hand, an increase in magnesium would reduce contraction and lead to
hypotension, peripheral respiratory muscle paralysis, and bradycardia. Consequently,
the normal contraction of cardiac muscles relies on the activity and availability of IMg
and may form the basis of a variety of cardiovascular disease states.

Chapter 1 - The role of ionised magnesium in cardiovascular function
AND PATHOLOGY

Page 22

1.5

M agnesium and cardiovascular disease

1.5.1

Hypertension

Given its physiological roles in the cardiovascular system it is not surprising that
magnesium deficiency has been implicated in the genesis of hypertension.
Animal studies provide evidence that lowering magnesium concentrations can result in
hypertensive events (15, 16, 89, 122). The mechanism of how magnesium regulates
blood pressure appears to be complex and includes inhibition of vasodilatory
prostaglandin release, regulation of calcium ion flux into the cell, and antagonising the
action of vasoconstrictors such as noradrenaline and angiotensin (141).

Altura et al (16) report that dietary deficiency of magnesium in rats results in the
elevation of arterial blood pressure, decreases in arteriolar, venular, and precapillary
lumen sizes, and decreased number of microvessels with a concomitant decrease of
blood flow in capillaries. An inverse relationship between lumen size and serum IMg
concentrations was found. Figure 1.7A represents vascular smooth muscle tone under
conditions of normal extracellular ionised magnesium and calcium concentrations.
As the ratio of calcium-to-magnesium increases (Fig. 1.7B), lumen size decreased and
contractile tension increased. Elevations of IMg concentrations above the physiological
level lowered baseline tension (Fig. 1.7C) (11, 122). Together, these findings suggest
that the concentration of IMg in the extracellular fluid, in vascular muscle cells and at
the vascular smooth muscle cell membrane has a significant role in controlling vascular
tone, contractility of blood vessels and subsequent prevention of hypertension (9).
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Figure 1.7
The effects on vascular smooth muscle of changes in extracellular
ionised magnesium concentration.
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R ep ro d u ced from reference (10).
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On average, patients with long term

hypertension have at least a 15% deficit in serum TMg (11). Inverse relationships
between total serum or tissue magnesium concentrations and arterial blood pressures
have been reported by a number of studies (15, 24, 43, 115, 126). Furthermore, these
authors demonstrate that intravenous infusion, or oral administration of magnesium salts
lowers the arterial blood pressure in hypertensive patients (14, 15, 24, 43).
For example, Altura et al (14) reports that the oral magnesium supplementation to
hypertensive patients with significant hypomagnesaemia lowered systolic and diastolic
blood pressures by up to 35 and 15 mm Hg, respectively. Moreover, they also stated
that there was a 15% decrease in serum IMg levels even in patients with borderline
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hypertension whilst serum TMg levels remained unchanged. This again emphasises that
the assessment of TMg as a guide for the therapeutic efficacy may not be reliable in all
cases. In a double blind placebo controlled study by Dyckner et al (47), patients on
chronic diuretic therapy were randomised to receive either magnesium or placebo.
Oral administration of magnesium to 20 patients on chronic diuretic therapy caused a
drop in blood pressure of 12/8 mm Hg at 6 months. The placebo group experienced a
drop in diastolic pressure of 4 mm Hg with no change in systolic pressure at 6 months.
The results from these studies demonstrate that magnesium supplementation may be of
value as an alternative to anti-hypertensive drug therapy.
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1.5.2

Atherosclerosis

Hypercholesterolaemia is widely accepted as a strong risk factor for the development of
both atherosclerosis and ischaemic heart disease. The focal accumulation of lipids,
complex carbohydrates, blood and blood products, fibrous tissue, and especially
calcium deposits in an artery, results in atherosclerosis (126). However, it remains
unclear how lipoproteins, calcium, and macrophages gain access to the normally
impermeable arterial walls, resulting in the loss of contractility of vascular smooth
muscle. Evidence from both human and animal studies suggests that IMg may play a
role in regulating serum levels of lipids and lipoproteins (11, 111). Lower magnesium
intake is correlated with higher serum lipid levels (11). However, the mechanism of a
possible interaction between magnesium and lipid metabolism remains to be elucidated.

Several studies have confirmed that magnesium deficiency can intensify cardiovascular
lipid deposition and lesions and that dietary magnesium supplementation prevents
atherosclerosis (11, 111). Altura et al (11) have demonstrated that pre-treatment of
animals (rats and dogs) with developing atherosclerosis by administration of magnesium
had beneficial effects. Considerable lowering of serum cholesterol and triglycerides
occurred in normal as well as atherosclerotic animals.

In addition, compared to

controls, pre-treatment reduced the atherosclerotic process markedly and reduced
calcium in the arterial walls.

These findings suggest that IMg plays an important

regulatory role in controlling lipid metabolism in arterial walls (15).
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Furthermore, both in vivo and in vitro studies indicate that magnesium deficiency
affects the susceptibility of lipoproteins to peroxidation, resulting in the formation of
lipid peroxidation products.

Oxidised lipoproteins (e.g. oxidised very-low-density

lipoproteins and low-density lipoproteins) have been shown to be cytotoxic to cells in
culture (15). Altura et al (15) reports that these lipid peroxidation products appear in
rats and hamsters within a week after the initiation of a magnesium deficient diet.
Within 2 - 3 weeks, cardiomyopathic lesions appear to become prominent in both
animal models. Moreover, it has been shown that magnesium deficiency causes an
elevation in circulating levels of the inflammatory cytokines such as interleukin-1,
interleukin-6 and tumour necrosis factor-alpha, and endothelin concomitant with the
appearance of lipid peroxidation and myocardial damage (11, 110, 112). Collectively
this data suggest that magnesium deficiency significantly contributes to the vascular
injuries seen in atherogenesis and hypertensive disease that often leads to ischaemic
heart disease (110).

Clinical studies have shown that the thrombotic tendencies in atherosclerosis play
important roles in the “cracking and bleeding” of atherosclerotic plaques in patients
with LHD and AMI (11). High concentrations of magnesium have been demonstrated to
suppress thrombus formation. Several authors report that high doses of intravenous
administered magnesium can markedly decrease platelet aggregation at the site of
arterial constriction, and prevent formation of microthrombi in animals with narrowed
major coronary arteries (11, 27, 126, 148).
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1.5.3

Arrhythmias

Although there are several physiological effects of altered IMg levels in myocardial
tissue that may produce arrhythmias, the mechanism for the loss of normal cardiac
rhythm in arrhythmias is not fully understood. As described earlier, IMg is an essential
activator of the Na+/K+ ATPase pump, helping to maintain the resting potential across
the cell membrane (24, 26).

Magnesium deficiency is associated with loss of

intracellular potassium, an increase in intracellular sodium and an increase in cell
membrane excitability. An increase in intracellular sodium increases sodium-calcium
exchange, with a rise in intracellular calcium. The result is transient depolarisation of
the cell membrane and repetitive arrhythmias (49, 149, 150).

Figure 1.8 is a schematic representation of electrocardiograms in patients with normal
(A), moderately (B) and severely (C) lowered serum TMg levels. The electrocardiogram
is a record of the electrical activity of the heart and is a valuable tool for detecting
abnormal cardiac rhythm and myocardial damage. The electrocardiogram gives
important information concerning the spread of excitation of the different parts of the
heart.

Depolarisation of atrial muscle tissues cause atrial contraction generating a

so-called P wave. The Q, R and S waves (QRS complex) correspond to a wave of
depolarisation across the ventricular muscle. The T wave corresponds to ventricular
repolarisation (42).
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Figure 1.8
Comparison of electrocardiograms from patients with normal (A),
moderately (B) or severely lowered (C) serum total magnesium levels.

Reproduced from references (42, 126)

Patients with mild magnesium deficiency (serum TMg of < 0.70 mmol/L; normal range
0.70 - 0.90 mmol/L) exhibit a widening of the QRS complex, an increase in peak T
waves (Fig. 1.8B), and ST segment depression (Fig. 1.8C).

The more severe the

magnesium deficiency (TMg of < 0.65 mmol/L), the wider the QRS complex becomes
(Fig. 1.8C) and arrhythmias occur (128). The QT interval (i.e. beginning of the QRS
complex to the end of the T wave) which represents the total duration of ventricular
systole is delayed in magnesium-deficient patients (24). It is during this period that the
patient is highly vulnerable to cardiac arrhythmias resulting in myocardial infarction
and possible death (25, 149).

Table 1.5 summarises various kinds of arrhythmias

caused by low magnesium levels.
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Table 1.5
Various kinds of arrhythmias caused by low magnesium levels.

Ventricular tachycardia
Ventricular fibrillation
Torsade de pointes
Digitalis-induced arrhythmias
Paroxysmal atrial tachycardia
Atrial flutter and fibrillation
Multifocal atrial tachycardia
Reproduced from reference (149)

Extensive clinical trials have been carried out in patients with AMI to investigate the
value of treating arrhythmias with magnesium (29, 39, 69, 104, 109, 130, 132, 138, 146,
148). In each double-blind placebo-controlled study, patients with suspected AMI were
randomised to receive either magnesium or placebo immediately on admission to
hospital.

These studies concluded that there are significant reductions of complex

arrhythmias in patients treated with magnesium. On average, 44% of patients from the
placebo groups exhibited arrhythmias, compared to only 24% in the group given
magnesium. In addition, the latter group had a 49% reduction in the incidence of
ventricular tachycardia and fibrillation. A further striking finding in these studies was
the higher mortality rate (from 2% to 14%) in the placebo group.
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1.5.4

Ischaemic Heart Disease and Acute Myocardial Infarction

Myocardial ischaemia, or inadequate blood flow to the heart, may lead to angina
pectoris and myocardial infarction (i.e. a condition caused by partial or complete
occlusion to one or more of the coronary arteries) (137). There are many causes of
IHD, but the most common cause is coronary atherosclerosis (126, 137).

The available data suggest that deficiency in cardiac and vascular tissue IMg does play a
role in the aetiology of atherosclerosis, arrhythmias and hypertension. Thus, it would be
anticipated that a large number of patients with IHD and AMI would have blood,
cardiac and vascular tissue deficiency of magnesium.

However, the prevalence of

magnesium deficiency in patients with ischaemic heart disease and acute myocardial
infarction has not yet been well established. Several reports indicate that serum TMg
concentrations are reduced in patients with AMI (58, 108), while other studies have
observed normal serum TMg concentrations (78). Ott et al (104) concluded in a review
that hypomagnesaemia associated with AMI may be transient, and serum TMg
concentration may become normal after the acute phase of AMI (109, 132).
Nevertheless, the most consistent data has been noted in cardiac tissue of patients who
died of sudden death ischaemic heart disease. In these patients, a mean 20% loss of
TMg in cardiac tissue has been reported (15,40,49, 144).

Current studies have revealed that a great deal of the inconsistencies in published
reports has been due to the inability to measure serum IMg. Recent reports by Altura et
al (8, 10) clearly demonstrate for the first time, consistent deficits in serum IMg in
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many IHD patients. In a double-blind study Altura et al (8) have shown that a high
incidence of hospitalised patients clearly exhibit low serum IMg levels. For example,
83% of patients admitted with coronary artery disease and AMI exhibited low serum
IMg, but normal serum TMg.

1.5.4.1

Magnesium as a pharmacological agent in acute
myocardial infarction

Acute myocardial infarction is another condition for which randomised and placebo
controlled trials of magnesium therapy have been undertaken.

Currently, the

pharmacological role of magnesium in myocardial infarction remains controversial,
with further studies needed (127). Different studies (of up to 1,300 patients per study)
have reported little or no benefit to as much as an 89% reduction in the short-term
mortality rate after magnesium infusions, in patients with suspected AMI (1, 39, 67, 69,
70, 87, 109, 130, 133, 138, 146).

The Second Leicester Intravenous Magnesium

Intervention Trial (LEMIT-2) (2,316 patients) showed that magnesium infusion has
clinical efficacy (153, 154). Table 1.6 summarises the protocol and findings of the
LIMIT-2. The trial reported a 24% reduction in 28-day mortality in patients with AMI
treated with magnesium. Magnesium-treated patients also had a 25% lower incidence
of congestive heart failure, suggesting that magnesium has a direct protective effect on
the myocardium. Moreover, the long term results from LIMIT-2 revealed a 21% lower
rate of ischaemic heart disease in the magnesium-treated group over 4 years (20, 148).
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Table 1.6
Summary of LIMIT-2 and ISIS-4 protocols and findings.

LIMIT-2
(n=2,316)
Double-blind, placebo
controlled

Open control (non-blind, no
placebo)

36%

70%

Dose

8 mmol loading dose over 5
minutes, plus 65 mmol infusion
over 24 hours.

8 mmol loading dose over 15
minutes, plus 72 mmol infusion
over 24 hours

Timing requirements

Loading dose before any
thrombolysis

Randomised after completion of
lytic phase*

Median time from the
Onset of symptoms to
randomisation

3 hours

8 hours

Study design
Patients receiving
thrombolysis

ISIS-4
(n=58,050)

Magnesium Protocol

Outcome

Short term

25% relative reduction in LVF
5.5% relative increase in 5-week
in CCU (P = 0.009).
mortality in magnesium group
24% relative reduction in 28-day (2P = 0.07)
mortality in magnesium group
(P = 0.04)
0.36% mortality excess at
16% decrease in all-cause
Long Term
median 15 months in
mortality at 1.0-5.5 (mean 2.7)
magnesium group
years in magnesium group
(P - 0.03)
The first hour or so of any fibrinolytic regimen. LVF = left ventricular failure;
CCU = coronary care unit. Adapted from reference (28,131).

Contrary to the LIMIT-2 study, the Fourth International Study of Infarct Survival
(ISIS-4) study of 58,050 patients found no improvement in short-term mortality rates
following magnesium therapy in patients with AMI (75, 76). Table 1.6 summarises the
protocol and findings of ISIS-4. The mortality rate was 7.6% in the magnesium treated
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group and 7.2% in the control group, suggesting no mortality benefit of magnesium
administration (75, 76, 126).

Several important differences between the protocols used in ISIS-4 and LIMIT-2 have
evoked controversy.

The timing of magnesium administration and thrombolytic

treatment are two major differences between trials that may explain the disparities in
results. LIMIT-2 protocol specified that magnesium infusion be started as soon as
possible after onset of symptom and that in cases where a fibrinolytic agent was used, it
was to be provided after or at the same time as the magnesium infusion. Woods et al
(154) attributed the 24% reduction in the 28-day mortality in LIMIT-2 to the prompt
administration of magnesium before thrombolysis.

Furthermore, early magnesium

treatment reduced left ventricular failure, which may explain the 21% reduction in
mortality over a mean follow-up of 2.7 years. ISIS-4 protocol on the other hand called
for administration of a magnesium infusion from several hours up to 12 hours after
commencement of thrombolytic therapy (127). Even slight delays in administering
magnesium may have lessened its beneficial effects.

The dosage of magnesium in the first 24-hour after AMI may also contribute to the
differences between the two trials. The administration of magnesium at a level greater
than the therapeutic threshold can cause hypermagnesaemia. Generalised vasodilation
due to hypermagnesaemia can cause profound hypotension, which could increase risk of
shock and extension of myocardial necrosis (59, 129).

In the LIMIT-2 study,

magnesium dosage was 73mmol/24hr and hypermagnesaemia was not a problem.
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However, in the ISIS-4 study the magnesium dosage was 80 mmol/24hr, and
hypotension was significantly more frequent in patients treated with magnesium than in
the control group. Thus, the amount of magnesium infused over 24 hours could be
another factor affecting morbidity and mortality.
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1.6

Project aims

Survival of patients with AMI is dependent on the quick and accurate diagnosis.
A rapid diagnosis improves the physician’s ability to minimise cardiac damage by
thrombolytics or emergency surgery. However, in a large percentage (approximately
30%) of patients with chest pain, the correct detection or exclusion of AMI depends
entirely on biochemical tests such as CK-MB and ECG recordings.

Serum magnesium concentrations have been reported by a number of authors to
decrease in patients with AMI (2, 14, 34, 35, 46, 58, 66, 72, 113).

If so, the

measurement of serum or whole blood IMg in a clinical setting may be a cost-effective,
simple and rapid means of providing an accurate diagnosis. With the development of
ion selective electrodes, it is now possible to measure the ionised or biologically active
form of magnesium in urine, plasma, serum and whole blood.

The aims of this study are:
(i)

to validate the analytical precision of the AVL 988-4 analyser’s magnesium ion
selective electrode (Chapter 2).

(ii)

to determine the effects of duration and temperature of storage on the stability of
IMg in serum and whole blood samples (Chapter 3).

(iii)

to measure IMg, TMg and CK-MB in non-AMI and AMI groups, to evaluate
any trends in IMg associated with AMI, and to determine if IMg concentrations
could be used as a diagnostic tool for AMI (Chapter 4).
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Chapter 2 A n a l y t ic a l p r e c is io n o f t h e
A V L 9 8 8 -4 ANALYSER FOR
MEASURING IONISED MAGNESIUM

2.1

I ntroduction

Understanding of magnesium metabolism in health and disease has been compromised
by the lack of appropriate technology to determine IMg. Several technologies that have
recently emerged for determining IMg concentrations in tissue and body fluids include
Nuclear Magnetic Resonance Spectroscopy (NMRS), Fluorescent Probes (FP) and IonSelective Electrodes (ISE).

NMRS has been used to determine intracellular IMg in a variety of tissues (35, 92).
This technique takes advantage of differences in NMR spectral characteristics of the
two species of ATP (free ATP and Mg2+-ATP) present in the cell. By using a 31P probe,
it is possible to distinguish and quantitate ATP and Mg2+-ATP (38, 124, 125). The
estimation of intracellular IMg concentration is based upon measurement of the
frequency differentiation between alpha phosphorus and beta phosphorous resonances
and depends on the extent of complexation between magnesium and ATP (61). The
accurate assessment of intracellular IMg concentration also depends on the choice of
stability constant for Mg2+-ATP, which is still a matter of dispute (102, 117). Although
extremely sensitive such a method is not currently cost-effective or sufficiently rapid for
diagnosis of AMI.

FP are used to determine intracellular IMg concentration (107, 145). FP are compounds
that selectively bind magnesium and concomitantly undergo spectral changes. Furaptra
is a FP that exhibits a shift in the peak excitation wavelength for fluorescence when
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bound to magnesium. The change in fluorescence corresponds to the IMg concentration
(44, 50).

It should be mentioned that changes in intracellular ATP or pH affect the complexation
of magnesium and ATP (NMRS technique), and magnesium and the FP (FP technique),
potentially giving incorrect readings (50, 51). This characteristic renders it difficult to
use the above techniques for IMg determination during ischaemia where both
intracellular pH and ATP change drastically.

Currently, ISE constitute the most suitable means for rapidly assessing IMg levels in
clinical practice. ISE are relatively inexpensive potentiometric devices and are widely
used for the routine monitoring of various analytes (e.g. calcium, potassium, chloride,
magnesium and sodium) in serum, plasma and whole blood (103, 134). The fast and
reproducible response that these electrodes exhibit can also provide real-time
monitoring of these analytes in a clinical laboratory.

The ISE measurement principle is based on the measurement of a potential that
develops across a selective membrane.

The ion selective membrane separates the

sample whose electrolyte concentration is unknown from an electrode solution whose
electrolyte concentration is known. An ionophore (a chemical material that has a high
affinity for a particular ion) incorporated into the ISE reacts selectively with the ion of
interest. This in turn generates an electrochemical potential on both the outer membrane
surface, which is exposed to the sample, and the inner membrane surface, which
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contacts the inner filling solution of the ISE. The potential of the inner surface of the
membrane is kept constant whilst the only potential change measured in the circuit is
the potential of the membrane surface in contact with the sample. Thus, the potential
difference is related to the ion concentration in the sample (50, 51, 79).

Previous studies have shown that there are problems with IMg ISE that may affect their
clinical usefulness (52, 53, 71, 114, 157). Apart from the limited lifespan of the IMg
ISE, the major difficulty of the IMg ISE is the insufficient selectivity of the ionophore
for IMg over other cations found in the plasma matrix, mainly ICa. To overcome this
difficulty the instrument carries out a chemometric procedure, i.e. it measures ICa
(adjusted to a normal pH of 7.4) and mathematically adjusts IMg for it.

If ISE measurement of EMg is to be useful for the diagnosis of AMI, the data obtained
must be reproducible and accurate.

At present three companies (AVL in Austria,

KONE in Finland and NOVA in the United States) are developing an IMg ISE for
clinical use. The AVL 988-4 analyser was used for this study as it had the longest ISE
lifespan, the widest analytical range and required the least amount of sample and time
for analysis.

The aim of this study was to verify previous precision studies on the AVL IMg ISE.
In contrast to other precision studies that only used artificially produced quality control
solutions (52, 71, 157), human serum samples were also used to evaluate precision.
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2.2

Materials and Methods

2.2.1

The AVL 988-4 Analyser

The AVL 988-4 analyser (AVL Medical Instruments, Melbourne, Australia Pty Ltd)
containing the specially designed ionophore (neutral carrier ETH 7025), was used to
obtain all IMg concentrations in this study.

The analyser determines pH and the

concentrations of IMg, ICa and ionised sodium (INa), in mmol/L. Six measurement
(sample types) modes are available on the analyser, they are whole blood, serum,
standard (calibrator), urine, dialysis solution and quality control materials. A 120 jiL
sample is required to measure the four analytes, and results are available 90 seconds
after sample introduction.

The AVL 988-4 IMg ISE measures IMg concentrations

ranging from 0.1 - 3.0 mmol/L.

The AVL 988-4 analyser has four standard solutions, namely Standard A, Standard B,
Standard C and Standard D. Table 2.1 lists the concentration of each analyte in the
supplied Standard solutions. A fully automatic 1-point calibration is performed with
every measuring cycle, with multiple point calibrations performed every 3 hours. Every
24 hours the analyser performs a 4-point calibration for IMg.
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2.2.2

Samples

To determine analytical precision three commercial protein-based control solutions and
three human sera were used. The three protein-based control solutions (ISE-trol 1, ISEtrol 2, and ISE-trol 3 - Code HC0033) contained different concentrations of IMg, ICa,
INa and pH. The concentrations of all analytes in the different solutions are given in
Table 2.1.

Table 2.1
Concentrations of each analyte in the supplied Standards and
ISE-trol control solutions.

Solution

IMg
(mmol/L)

ICa
(mmol/L)

INa
(mmol/L)

PH

Standard A

0.30

0.90

150.0

7.38

Standard B

0.30

1.25

100.0

7.00

Standard C

0.90

0.90

150.0

7.38

Standard D

0.30

0.90

100.0

7.38

ISE-trol Level 1

0.98-1.28

1.92-2.22

117-123

7.19-7.25

ISE-trol Level 2

0.52 - 0.72

1.21-1.51

144-150

7.38 - 7.44

ISE-trol Level 3

0.24 - 0.40

0.55 - 0.75

158-164

7.62 - 7.68

Serum samples were! collected from 15 volunteers.

Venous blood (7.5 mL) was

collected under anaerobic conditions by using the Monovette (Serum Gel) syringe
system (Sarstedt, Nümbrecht, Germany). The tubes contain no additives, except for an
inert gel layer that facilitates serum separation from the blood cells during
C h apter
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centrifugation.

Blood specimens were allowed to clot for 15 minutes at room

temperature after collection before being centrifuged in a Labofuge GL (Heraeus-Christ,
Gipsmuhlenweg, Germany) at 3500 rpm for 10 minutes. The IMg concentration was
determined in each sample in duplicate, and three were selected to cover the widest
analytical range possible. The three serum samples were identified as Serum A, B and
C. The sera were kept in capped 5 mL cups for the within-run precision study or
divided equally into 20 aliquots in capped 0.5 mL cups and frozen (-20 °C) for the dayto-day precision study.

Any haemolytic, icteric or turbid samples were discarded. Haemolysis (the breakdown
of red blood cells) falsely increases serum concentrations of analytes that are present in
high concentrations within the red blood cells, such as potassium and magnesium.
Icteric or turbid samples are potential analytical interferents (79).

The AVL 988-4 analyser automatically corrects for any interference by ICa and
calculates the ICa concentration adjusted to a normal pH of 7.4 for samples with pH
between 7.2 to 7.6. Consequently, there is a close chemical relationship between the pH
value of a blood sample and its ICa concentration. The pH value of a blood sample
varies due to exchange of C 02 with air. Hence, all samples needed to be kept in an
anaerobic environment to avoid artefactually elevated pH values, and therefore,
inaccurate ICa and IMg concentrations (36, 95, 122).
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2.2.3

Assessment

All samples were analysed only after maintenance, daily calibration and quality control
procedures were performed on the AVL 988-4 analyser, as recommended by the
manufacturer. Commercial protein-based control solutions (ISE-trols) and sera were
analysed in a continuous randomised order 20 consecutive times to assess within-run
precision. Analysing each protein-based control solution and sera in a randomised order
on 20 consecutive days performed the day-to-day precision study. On each day a new
ampoule of each protein-based control solution was opened and analysed immediately.
As well, an aliquot of each frozen serum was thawed for 30 minutes, mixed by gentle
inversion and analysed.

For the protein-based control solutions, the AVL 988-4

analyser was used in the Quality Control mode. For the sera, the analyser was used in
the Serum mode.

2.2.4

Statistical Analysis

For each precision study, the mean, standard deviation (SD) and coefficient of variation
(%CV) expressed as a percentage, were calculated for IMg for each protein-based
control solution and serum sample.
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2.3

Results

The within-run and day-to-day precision of the AVL 988-4 analyser is shown in
Table 2.2. For the protein-based control solutions, the standard deviations for withinrun and day-to-day precision studies were <0.012 mmol/L, and <0.043 mmol/L,
respectively.

The %CV for within-run precision was <2.30%, and for day-to-day

precision was <4.04%.

For the sera, the standard deviations for within-run and

day-to-day precision studies were <0.006 mmol/L, and <0.015 mmol/L, respectively.
The %CV for within-run was <1.05 %, and for day-to-day precision was <2.76%.

The best within-run CVs were obtained for solutions that have IMg within or close to
the physiological range (0.50 - 0.65 mmol/L). In comparison to the protein-based
control solutions, the serum samples exhibit the lowest CVs in both within-run and
day-to-day precision studies.

Table 2.2
Within-run and day-to-day precision of AVL 988-4 analyser for IMg.

IMg
Day-to-Day Precision

Within-Run Precision

Solution
n

Mean

SD

cv

n

Mean

SD

cv

20

1.07

0.043

(%)
4.04

(mmol/L)

ISE-trol 1

20

1.12

0.012

(%)
1.05

ISE-trol 2

20

0.61

0.006

0.98

20

0.56

0.018

3.15

ISE-trol 3

20

0.28

0.006

2.30

20

0.27

0.008

2.81

Serum A

20

0.45

0.005

1.05

20

0.44

0.012

2.76

Serum B

20

0.54

0.005

0.94

20

0.54

0.012

2.30

Serum C

20

0.60

0.006

0.95

20

0.60

0.015

2.50

(mmol/L)
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2.4

Discussion

This study compared the precision of the IMg ISE with the findings of other
investigators. The precision of the AVL analyser for IMg in this study is consistent
with four other reports also using the ISE-trol protein-based solutions. The study by
Elin et al (52) of the AVL 988-4 analyser reported within-run and day-to-day CVs for
IMg of <3.00% and <6.40%, respectively.

In the study by Zoppi et al (157) the

within-run IMg CVs range from 0.67% to 3.00% and the day-to-day precision range
between 3.91% to 5.89%. Hristova et al (71) reported within-run IMg CVs for low,
medium and high controls of 2.60%, 0.77% and 1.07%, respectively, and the day-to-day
CVs for low, medium and high of 2.63%, 3.06% and 4.93%, respectively. Filos et al
(54) reports within-run and day-to-day precision CVs of <3.05 and <6.40%,
respectively.

In all cases, the within-run imprecision was less than the day-to-day

imprecision.

In this study, the within-run IMg CVs for low, medium and high protein-based control
solutions are 2.30%, 0.98% and 1.05%, respectively. The day-to-day CVs for low,
medium and high protein-based solutions are 2.81%, 3.15% and 4.04%, respectively.
Estimation of analyser precision on human serum samples was important because of
matrix differences and the heterogeneity of serum samples, compared with proteinbased control solutions. The CVs obtained using serum samples were equal to or lower
than those obtained with the protein-based control solutions. The within-run CVs for
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Serum A, B and C were 1.05%, 0.94% and 0.95%, respectively. The day-to-day CVs
for Serum A, B and C were 2.76%, 2.30% and 2.50%, respectively (Table 2.2).

In conclusion, from the analysis of the protein-based control solutions and serum
samples, this precision study confirms that the precision of the AVL IMg ISE was
suitable for the sequential monitoring of serum IMg concentrations in the clinical
diagnostic setting.
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Chapter 3 E f f e c t o f d u r a t io n a n d
TEMPERATURE OF STORAGE ON
STABILITY OF IONISED MAGNESIUM IN
SERUM AND WHOLE BLOOD

3.1

Introduction

For clinical work, and future studies, it is essential that storage variables be investigated
in samples for IMg analysis. The determination of IMg using ISEs is a potentially
valuable new tool for studies of magnesium metabolism, yet little is known about the
stability of IMg in serum and whole blood on storage. Incomplete and controversial
data exists about the reproducibility of serum and whole blood IMg after storage, with
only passing reference to the effect of time on the result obtained (65).

Under certain clinical situations, there are advantages to using either serum or whole
blood. Whole blood samples have the advantage in that under urgent conditions they
can be analysed immediately without time lost waiting for coagulation and
centrifugation. However, the storage life of whole blood is generally much shorter than
serum due to complex factors such as leaching of intracellular ions and proteins, and
cell lysis, that affect its stability. One important factor to consider is the continued
metabolism by leukocytes and erythrocytes during storage, which will lower glucose
levels, increase lactic acid levels and lower the pH. As discussed in Chapter 2, the
AVL 988-4 analyser mathematically corrects the IMg concentration for pH and ICa
concentration. For these reasons, it is important to determine how long whole blood
samples can be stored without affecting EMg stability. On the other hand, the absence
of cells means that serum samples can generally be stored for longer periods, which
therefore allows flexibility in time of analysis.
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The aims of this study were to determine the most suitable condition for storage of
serum and whole blood samples for the subsequent determination of IMg, to determine
the extent to which these sample types deteriorate over time and to determine if there
are any differences in IMg concentration, irrespective of whether one samples whole
blood or serum.
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3.2

Materials and Method
3.2.1

Instrument

Ionised magnesium in serum and whole blood was measured on the AVL 988-4
analyser, as described in Chapter 2, Section 2.2.1, page 41.

3.2.2

Serum Samples

Venous blood (7.5 mL) was collected from 10 volunteers under anaerobic conditions by
using the Monovette (Serum Gel) syringe system. A copy of the Consent Form and the
Collection Protocol are reproduced in Appendix A and B, respectively. The blood was
allowed to clot for at least 15 minutes at room temperature after collection and
centrifuged at 3500 rpm for 10 minutes. Serum was separated and analysed in duplicate
for IMg concentration. The remaining serum from each specimen was divided into 21
equal aliquots in capped 0.5 mL cups and stored at either -20 °C, 4 °C or room
temperature.

3.2.3

Whole Blood Samples

Venous blood (4.0 mL) was collected from seven volunteers under anaerobic conditions
using the specially designed Monovette syringe systems (Sarstedt, Numbrecht,
Germany).

These collection tubes contained ISE-balanced heparin (anti-coagulant).

The heparin is titrated with calcium, which limits errors in the determination of IMg.
After collection, the samples were immediately analysed in duplicate for IMg
concentration. Each sample was then divided into 12 equal aliquots in capped 0.5 mL
cups and stored at either 4° C or at room temperature.
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3.2.4

Assessment

Samples were analysed after maintenance, daily calibration and quality control
procedures were performed on the AVL 988-4 analyser, as recommended by the
manufacturer. For the serum study, an aliquot from each group was brought to room
temperature, mixed by gentle inversion and analysed on each day for seven days.
Samples were measured in the Serum mode. For the whole blood study, an aliquot from
each group was brought to room temperature, mixed by gentle inversion and analysed at
30-minute intervals for 180 minutes after collection. Samples were measured in the
Whole Blood mode. For the comparison study between serum and whole blood IMg,
two venous blood samples were collected as outlined in Sections 3.2.2 (Serum Sample)
and 3.2.3 (Whole Blood) from 50 volunteers. Samples were analysed within 30 minutes
of collection in the Serum or Whole Blood mode.

3.2.5

Statistical Analysis

The mean, standard deviation (SD) and standard error of the mean (SEM) were
calculated for IMg, at each time interval tested, for each sample type and storage
condition.

For the comparison between serum and whole blood study, statistics were obtained by
linear regression analysis.

As the data were not normally distributed, the Mann

Whitney Rank Sum Test (two-sample test) was employed for assessment of differences
in serum and whole blood IMg concentrations. Significant differences between group
means were inferred for P <0.05.
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3.3

Results

3.3.1

Serum Samples

Figure 3.1 shows the stability of serum IMg concentration during 7 days of storage at
room temperature, 4 °C or -20 °C. All points are the mean of ten serum samples.
Initially, the mean serum IMg concentration was 0.53 ± 0.06 mmol/L. The shaded area
indicates a 4.04% CV, the day-to-day precision (from Chapter 2). After 7 days of
storage at room temperature, 4 °C and -20 °C, there was a decrease of 3.4%, 2.3% and
0.95% in serum IMg concentration, respectively. The standard deviation after seven
days of storage at room temperature, 4 °C and -20 °C was 0.07 mmol/L, 0.06 mmol/L
and 0.05 mmol/L, respectively.

Figure 3.1
Mean (±SEM) serum IMg concentrations during 7 days of storage.
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3.3.2

Whole Blood Samples

Figure 3.2 illustrates the stability of whole blood IMg over 180 minutes when stored at
room temperature or at 4 °C. All points are the mean of seven whole blood samples.
Initially, the mean whole blood EMg concentration was 0.54 ± 0.06 mmol/L.
The shaded area indicates a 4.04% CV, the day-to-day precision.

From 0 to 120

minutes there was a decrease of 1.3% in whole blood IMg concentration, at both storage
conditions. The standard deviation after 120 minutes of storage at room temperature or
at 4 °C was 0.06 mmol/L.

Figure 3.2
Mean (+SEM) whole blood IMg concentrations during 3 hours of storage.
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From 0 to 180 minutes, there was a decrease of 10.8% in whole blood IMg
concentration, stored at room temperature. At 4 °C there was a decrease of 3.0% in
whole blood IMg concentration. The standard deviation of samples after 180 minutes of
storage at room temperature or 4 °C was 0.06 mmol/L.

3.3.3

Serum and Whole Blood Sample Comparison

A correlation study was performed on measurements of serum and whole blood IMg
(Figure 3.3). The slope was 1.001 and the intercept was -0.006 mmol/L. The data had
a correlation coefficient (r) of 0.983 and standard error of the regression (Syx) of 0.013.
Furthermore, the mean values for IMg obtained from serum and whole blood are
virtually identical, 0.57 ± 0.07 mmol/L and 0.56 ± 0.07 mmol/L, respectively. There is
no significant (P = 0.674) difference between the IMg concentrations obtained from
serum or whole blood.
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Figure 3.3
Correlation between serum and whole blood IMg concentration.
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3.4

D is c u s s io n

The criterion for IMg stability was the day-to-day precision of the ISE. If the precision
of serum results obtained over the seven-day period remained within the day-to-day
precision (CV of <4.04%), obtained in Chapter 2, then they were considered the same as
the initial values. Serum sample stability was acceptable over a seven-day period at all
temperatures tested. Results for the specimens did not exceed the 4.04% CV limit.
However, although all storage temperatures were within the acceptable limits, the best
results obtained were from those samples stored frozen at -20 °C. After seven days at
-20 °C, these samples had the lowest percentage decrease (0.95%) in IMg concentration
from initial values.

These finding are consistent to the values obtained by Halpem et al (65). Halpem’s
group examined 10 sera stored for 10 days, refrigerated at 4 °C and frozen at -15 °C,
using the AVL 808-4 analyser. On the tenth day, the mean IMg concentration did not
vary more than 0.40% from the initial value for both storage conditions. Likewise,
Halpem et al

(65) concluded that IMg reproducibility was good at both storage

temperatures. However, the lower standard deviation (±0.02 mmol/L) obtained from
the frozen samples was enough to consider freezing as the better storage condition.

Refrigerated whole blood samples were acceptable for analysis up to 180 minutes of
storage, with mean results not exceeding the 4.04% CV limit. At 180 minutes of
storage at 4 °C, there was a 3.0% decrease in IMg concentration from initial values.
By comparison, there was an unacceptable 10.8% decrease in IMg concentration in
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those samples stored at room temperature, with results exceeding the 4.04% CV limit.
The best results obtained were from those samples stored up to 120 minutes. There was
a decrease of 1.3% in IMg concentration, from the initial value. Previous studies have
failed to determine the IMg reproducibility in whole blood after storage. This study has
shown that whole blood can be stored refrigerated for up to 180 minutes without
jeopardising sample stability for IMg.

The present study compares for the first time data from serum and whole blood samples
measured for IMg concentration by the AVL 988-4 IMg ISE. The data shows no
significant (P = 0.674) difference in IMg concentration between the two sample types.
The calculated regression coefficient and intercept did not differ significantly from 1
and 0, respectively (Syx = 0.013). Similar findings have been reported by Altura et al
(8, 18) for plasma, serum and whole blood using a NOVA Stat Profile 8 (NOVA
Biomedical, Waltham, Massachusetts) and KONE (KONE, Espoo, Finland) analysers.

In conclusion, the results of this study confirm that within a clinical laboratory setting
and for future studies, it is possible to batch appropriately stored samples and process
them when convenient without affecting sample stability and IMg reproducibility.
Furthermore, the results in IMg concentration, obtained from either serum or whole
blood samples, are nearly identical, indicating that, depending upon the urgency for IMg
determination, either sample type may be used.
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C hapter 4 T he m ea sur em en t of
SERUM IONISED MAGNESIUM
FOR THE DETECTION OF
ACUTE MYOCARDIAL INFARCTION

4.1

In t r o d u c t i o n

After the onset of clinical symptoms in patients with AMI there is a time lag period
during which enzymes released from the damaged myocardial tissue increase in serum.
The quantitation of myocardial isoenzymes, for example CK-MB, is used as an aid in
the diagnosis of myocardial injury (30, 73, 147). Figure 4.1 shows a representative
serum CK-MB concentration profile following myocardial infarction. A serial rise and
fall in CK-MB is characteristic of myocardial infarction. CK-MB levels rise 3 to 8
hours following the onset of chest pain, with peak concentration obtained within 10 to
24 hours, returning to normal range within 24 to 48 hours (79). However, there are
several limitations to using measurements of CK-MB. Albeit in small quantities, CKMB is present in other tissue, such as skeletal muscle, and therefore a rise in CK-MB is
not always indicative of AMI. Skeletal muscle regenerative processes due to injury, for
example, elevate serum CK-MB proportionally (23, 81, 142). Furthermore, conditions
such as cardiac surgery for coronary bypass, valve replacement, polymyositis, muscular
dystrophies, chronic renal failure with dialysis, repair of congenital defects or any cause
of acute and chronic muscle injury have been reported to cause elevated serum CK-MB
levels (79). In these cases, however, the CK-MB levels do not exhibit the characteristic
rise and fall associated with myocardial injury, but care still needs to be taken not to
confuse these elevated CK-MB levels with genuine cardiac injury.

It has been

suggested that calculating the percentage of CK-MB in relation to total CK can be used
to determine whether elevations of CK-MB are of skeletal muscle or cardiac origin.
This strategy suffers from substantial loss of sensitivity if patients have both cardiac and
skeletal muscle damage (106).
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Figure 4.1
Representative serial serum CK-MB concentration profile following
myocardial infarction. Time 0 represents the onset of chest pain.

One marker that is currently under investigation and now challenges CK-MB as the
gold standard for detection of myocardial injury is cardiac troponin-I (cTn-I). Troponin
is a contractile regulatory protein complex present in striated muscle. Troponin is a
complex of three proteins, troponin-C (calcium binding component), troponin-I
(inhibitory component), and troponin-T (tropomyosin binding component), that act
together to regulate calcium-dependent interactions between myosin and actin, and
therefore regulate muscle contraction (22). Cardiac troponin-I has been shown to have
complete (100%) specificity to cardiac muscle (3, 22). Several reports indicate that
cTn-I concentrations increase above the reference range within 4 to 8 hours following
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chest pain. The cTn-I level peaks at 12 to 48 hours and remains elevated for 7 to 9 days
following AMI (4, 85). Its high specificity for the myocardium suggests that troponin-I
may replace CK-MB in any setting where the specificity of CK-MB is in doubt.
Several reports also indicate that apart from its diagnostic value, the analysis of cTn-I
has prognostic value in patients with unstable angina and cardiac disease (21, 60, 156).
For example, Antman et al (21) reports that elevated serum cTn-I concentrations, on
admission, may predict death by 42 days in unstable angina and improved survival with
an early invasive strategy.

Although the diagnosis of AMI is straight forward when anginal pain is accompanied by
typical changes on the ECG, thrombolytic therapy needs to be administered rapidly
before AMI is confirmed by more time-consuming measurements of cardiac markers
such as CK-MB (119, 143). However, in approximately 30% of all patients with chest
pain, the ECG on admission is non-diagnostic (19, 62).

A correct diagnosis of

myocardial cell injury depends entirely on the result of biochemical assays.

Serum TMg concentrations in AMI have been studied on some occasions. While some
reports could not demonstrate any significant changes in the serum TMg concentration
after the onset of myocardial infarction, most studies have shown a significant decrease
(2, 14, 34, 35, 46, 58, 66, 72, 113). However, those studies that had found a significant
change in the level of serum magnesium failed to determine the value of this test as an
aid in the diagnosis of AMI. Ionised magnesium may prove to be of clinical value as a
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tool in diagnosing AMI and may be extremely beneficial in the management of these
patients.

The present investigation was performed to establish serum IMg, TMg and CK-MB
levels in AMI and non-AMI patients. The objective was also to compare serum IMg to
one of the current cardiac markers, CK-MB, and from this to determine if IMg may be
used as a diagnostic tool for myocardial infarction.
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4.2

M aterials and M ethods

4.2.1

Analytical Methods

4.2.1.1

Ionised magnesium determination

Ionised magnesium in serum was measured on the AVL 988-4 analyser, as described in
Chapter 2, Section 2.2.1, page 41.

4.2.1.2

CK-M B determination

CK-MB in serum was measured on the ACS: 180, Automated Chemiluminescence
System (Ciba Coming Diagnostics Corp. Medfield, Massachusetts). The Ciba Coming
CK-MB II assay is a two-site chemiluminometric (sandwich) assay, which uses
constant amounts of two antibodies.

The first antibody

(‘Lite’ Reagent) is a

monoclonal mouse anti-CK-MB antibody labelled with acridinium ester. The second
antibody (Solid Phase) is a monoclonal mouse anti-CK-BB antibody covalently
coupled to paramagnetic particles. A direct relationship exists between the CK-MB in a
sample and the relative light units detected by the ACS: 180 system. The assay is
unaffected by increased levels of the other CK isoenzymes.

A 100 pL sample is

required for analyses and the results are available approximately 15 minutes after
sample introduction. The ACS CK-MB II assay measures CK-MB concentrations
ranging from 0.65 pg/L to 500 pg/L, the normal levels are typically <5 pg/L.
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4.2.1.3

Total magnesium determination

Total magnesium in serum was measured on the Vitros 700 Analyser (Johnson &
Johnson Clinical Diagnostics, Inc., Rochester, New York).

The Vitros magnesium

Slides (dry chemistry) quantitate magnesium concentration in serum, plasma and urine,
colorimetrically. A 10 jiL drop of sample is required to react with the formazan dye
derivative on the Vitros magnesium Slide and the results are available after
approximately 5 minutes.

The high magnesium affinity of the dye dissociates

magnesium from binding proteins and the resulting magnesium-dye complex causes a
shift in the dye absorption maximum from 540 nm to 630 nm, the reflection density of
the coloured complex is measured spectrophotometrically. The amount of dye complex
formed is proportional to the magnesium concentration. The Vitros magnesium assay
measures TMg concentrations ranging from 0.08 - 4.11 mmol/L; in our laboratory the
normal reference range is 0.71 - 0.90 mmol/L.

4.2.2

Sample Collection

An initial sample from each patient was collected in the Emergency Department after
AMI was suspected and/or diagnosed. Subsequent samples were collected during the
patients’ stay in Coronary Care Unit (CCU) and/or Sub-Acute Coronary Care Unit
(SACCU). Blood samples were obtained at least every 6 to 8 hours for up to 66 hours in
the AMI group and up to 36 hours in the non-AMI group. Venous blood (7.5 mL) was
collected under anaerobic conditions using the Monovette (Serum Gel) syringe system. A
copy of the Collection Protocol is reproduced in Appendix B. Blood was allowed to clot
for at least 15 minutes at room temperature after collection and centrifuged at 3500 rpm
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for 10 minutes.

Samples for TMg and CK-MB were stored at 4 °C until analysis.

Samples were assayed within 8 hours after collection. For IMg, serum samples were
stored at —20 °C for up to 3 days before batch analysis.

4.2.3

Statistical Analysis

The mean, standard deviation (SD) and standard error of the mean (SEM) were
calculated for IMg, TMg and CK-MB at each time interval monitored, for both the AMI
and non-AMI groups.

The selection of the appropriate statistical tests used was dependent on a number of
assumptions about the condition of that data. It was determined that the data did not
follow a normal distribution and the statistical analysis would have to employ
nonparametric tests.

The Mann-Whitney Rank Sum Test (two-sample test) was

employed for assessment of differences in either IMg or TMg levels between the AMI
and non-AMI groups. Significant differences between group means were inferred at
P <0.05.

The Kruskal-Wallis One Way Analysis of Variance on Ranks was employed for
assessment of differences (intergroup) in both IMg and TMg concentrations in the AMI
and non-AMI groups, at each 6 hour time interval monitored. Significant differences
between group means were inferred at P <0.05.
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4.3

Results

4.3.1

Patients

One hundred and sixty-two patients who were admitted consecutively to the CCU and
SACCU, Illawarra Regional Hospital (Wollongong, NSW, Australia), with a provisional
diagnosis of AMI, were studied. The 106 male and 56 female patients, ranging in age
from 25 to 90 years, gave written informed consent to participate in the study after a
thorough explanation of the study protocol. A copy of the Consent Form is reproduced in
Appendix A. The Ethics Committee of the University of Wollongong (Wollongong,
NSW, Australia) approved this investigation.

Some of the clinical characteristics of the patients studied are described in Table 4.1.
Retrospective investigation of medical records revealed that 50 male and 22 female
patients, ranging in age from 39 to 90 years (mean age 68.4 ± SD 12.9 years) had AMI.
Hereafter, these patients will be referred to as the AMI group. The diagnosis of AMI was
made by the clinicians responsible for the patient based on the criteria established by the
World Health Organization (155). These criteria include patient history, the presence of
typical and atypical chest pain, unequivocal changes in the ECG and increased
concentrations of CK-MB on serial blood collections. The remaining 56 males and 34
females, ranging in age from 25 to 88 years (mean age 68.1 ± SD 13.0 years), suffered
from chest pain in which a diagnosis of AMI was ruled out. Hereafter, these patients will
be referred to as the non-AMI group.
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Table 4.1
Clinical characteristics of patients studied.

AMI Group

Non-AMI Group

72

90

68.4 ±12.9

68.1 ±13.0

Male

50

56

Female

22

34

Previous AMI

10

11

Angina pectoris

20

28

n
Age (mean ± SD years)
Gender

History of Disease

CHF/IHD

18
None
24
CHF - Congestive Heart Failure; IHD = Ischaemic Heart Disease.

37
14

Table 4.2 shows the IMg, TMg and CK-MB data for all the patients studied. For AMI
patients, the data are further grouped according to an approximate time after the onset
after the chest pain. Fifty-seven of the AMI group presented sufficiently early that
values of CK-MB were either normal (n = 37) or were beginning to increase (n = 20),
permitting more complete data acquisition on the time course of changes in CK-MB
and IMg. All AMI patients followed the typical profile in serial CK-MB measurements
as described in Section 4.1. Maximum CK-MB values were obtained approximately
1 8 - 2 4 hours after the onset of chest pain. Within this time interval, the mean ± S.D
peak CK-MB value was 97.4 ± 101 jug/L (range 6.7 - >386 |Lig/L).
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Table 4.2
IMg, TMg and CK-MB concentrations of AMI and non-AMI patients.
Approx.
Hours
after
onset of
chest pain

No. of
subjects

Mean

SD

Range

Mean

SD

Range

Mean

SD

Range

0-6

20

0.512

0.043

0.45-0.60

0.759

0.062

0.65-0.86

6.7

12.7

0.5-54.8

6-12

44

0.517

0.057

0.43-0.74

0.777

0.082

0.58-0.91

20.6

40.1

0.3-252.5

12-18

18

0.514

0.046

0.44-0.59

0.773

0.089

0.60-0.86

37.6

42.9

0.2-161.6

18-24

72

0.476

0.051

0.38-0.60

0.762

0.088

0.58-0.91

97.4

101

6.7-386

24-30

20

0.479

0.058

0.39-0.58

0.761

0.088

0.64-0.94

75.8

86.3

12.5-301

30-36

43

0.503

0.049

0.39-0.60

0.762

0.081

0.60-0.92

57.2

73.1

3.9-319.9

36-42

31

0.507

0.047

0.39-0.60

0.771

0.082

0.64-0.93

42.3

54.6

2.8-210.5

42-48

23

0.510

0.055

0.40-0.66

0.775

0.039

0.73-0.85

34.7

30.2

4.7-78.0

48-54

9

0.515

0.022

0.47-0.54

0.753

0.040

0.70-0.81

18.4

16.4

5.5-46.0

54-60

12

0.514

0.047

0.45-0.59

0.760

0.075

0.66-0.87

10.2

10.4

2.9-30.6

60-66

11

0.519

0.045

0.42-0.57

0.754

0.080

0.54-0.87

6.4

4.4

1.1-13.2

Non-AMI

90

0.520

0.065

0.30-0.76

0.792

0.085

0.53-1.07

1.44

0.9

0.2-4.5

IMg (mmol/L)

4.3.2

TMg (mmol/L)

CK-MB (pg/L)

Serum CK-M B concentrations of non-AMI and AMI groups.

After the onset of chest pain, CK-MB concentrations were monitored to observe any
changes over time in both the non-AMI and AMI groups. It was important to observe the
timing and typical pattern of rise and fall (as described in Section 4.1) of CK-MB
concentrations in the AMI group studied, and to compare our observations with the
established representations of CK-MB changes associated with AMI.
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Figure 4.2 shows the mean concentrations of serum CK-MB in the non-AMI group over
time, with error bars indicating the SEM. The non-AMI group was monitored for up to
36 hours after the onset of chest pain.

Of the 90 patients diagnosed as not having

myocardial infarction, none had a value of CK-MB above the reference range (<5 pg/L)
throughout the monitoring period. The overall mean ± SD in CK-MB concentration of
the non-AMI group was 1.44 ± 0.91 pg/L. No significant difference (P = 0.979) in
CK-MB concentration was observed between each 6 hour time interval monitored.

Figure 4.2
Mean serum CK-MB concentrations of non-AMI patients.
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Figure 4.3 shows the mean concentrations of serum CK-MB in the AMI group over time,
with error bars indicating the SEM. All patients diagnosed with AMI had at least one
value of CK-MB above the reference range (>5 jig/L) during the monitoring period.
Of these 72 patients, 12 had only modest increases in peak CK-MB (all <25 jag/L), 55
had high CK-MB values (between 25 -3 0 0 jag/L), and the remaining 5 patients had very
high CK-MB values (>300 Jig/L).

Figure 4.3
Mean serum CK-MB concentrations of AMI patients.
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The data shows that CK-MB levels began to rise during the critical first 6 hours after the
onset of chest pain. Peak CK-MB concentrations (i.e. 97.4 ± 101 Jug/L) were observed by
1 8 - 2 4 hours. This was a 93.1% increase in CK-MB levels compared to initial values.
The observed pattern in CK—MB levels, after the onset of chest pain, agreed with
established CK-MB observations following AMI (30, 73, 147).

4.3.3

Serum TMg and CK-M B concentrations of non-AMI and AMI
groups.

A comparison was made between CK-MB and TMg levels for both the non-AMI and
AMI groups. Figure 4.4 shows the mean concentrations of serum TMg and CK-MB in
the non-AMI group over time, with error bars indicating the SEM. The overall TMg
concentration of the non-AMI group was 0.79 ± 0.09 mmol/L. Like CK-MB, TMg
concentrations did not significantly differ (P = 0.597) between each 6 hour time interval
monitored.
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Figure 4.4
Mean serum concentrations of TMg and CK-MB of non-AMI patients.

TMg
(mmol/L)

Time after the onset of chest pain
(Hours)

Figure 4.5 shows the mean concentrations of serum TMg and CK-MB in patients with
AMI over time, with error bars indicating the SEM. The overall TMg concentration of
the AMI group was 0.77 ± 0.08 mmol/L. Total magnesium concentrations remained
within the normal reference range (0.71 - 0.90 mmol/L) at each 6 hour time interval
monitored. Comparing the TMg concentrations of the AMI group at each 6 hour time
interval revealed no significant (P = 0.996) changes over the 66 hours of study. These
findings are in agreement with those authors (45, 82, 100, 152) reporting normal TMg
concentrations in patients with AMI and disagree with those authors (2, 14, 34, 35, 46, 58,
66, 72, 114) that report a decrease in TMg concentration in AMI patients.
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Figure 4.5
Mean serum concentrations of TMg and CK-MB of AMI patients.
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4.3.4

Serum IMg and TMg concentrations of non-AMI and AMI
groups.

A comparison was made between serum CK-MB and IMg levels for non-AMI and AMI
groups. Figure 4.6 compares the mean concentrations of serum IMg and TMg in the
non-AMI group over time, with error bars indicating the SEM.

The overall IMg

concentration of the non-AMI group was 0.52 ± 0.06 mmol/L.

Like TMg, IMg

concentrations remained within the normal reference range (0.50 - 0.65 mmol/L),
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throughout the 36 hours of study.

No significant difference (P = 0.276) in IMg

concentration was observed between each 6 hour time interval monitored.

Figure 4.6
Mean serum concentrations of IMg and TMg of non-AMI patients.
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Figure 4.7 shows the mean concentrations of serum IMg and TMg of patients with AMI
over time, with error bars indicating the SEM. From 0 to 18 hours after the onset of
chest pain, the IMg concentrations in the AMI group was within the normal reference
range (0.50 - 0.65 mmol/L). However, at the 18 - 24 and 24 - 30 hour time intervals,
IMg concentrations decreased to 0.48 ± 0.05 mmol/L (range 0.38 - 0.60 mmol/L) and
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0.48 ± 0.06 mmol/L (range 0.39 - 0.58), respectively. At the 1 8 -2 4 hour time interval,
this constituted a 7.0% decrease in serum IMg in the AMI group. The decrease in IMg
levels in the AMI group was significant (P <0.001) within the 66 hours of study.
Ionised magnesium levels then returned to normal levels by 30 - 42 hours. The overall
IMg concentration in the AMI group was also found to be 0.50 ± 0.05 mmol/L, which is
3.8% lower compared to the non-AMI group.

Altogether the AMI group had

significantly lower IMg and TMg concentrations (P <0.001 and P = 0.004, respectively)
compared to the non-AMI group.

Figure 4.7
Mean serum concentrations of IMg and TMg of AMI patients.
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4.3.5

Serum IMg and CK-MB concentrations of non-AMI and AMI
groups.

Figure 4.8 shows the serum IMg and CK-MB concentrations of non-AMI patients over
time, with error bars indicating the SEM.

Throughout the 36 hours of study both

analytes show little fluctuation and both remain within normal reference range.

Figure 4.8
Mean serum concentrations of IMg and CK-MB of non-AMI patients.
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Figure 4.9 shows the mean serum IMg and CK-MB concentrations of AMI patients
over time, with error bars indicating the SEM. Following the onset of chest pain IMg
and CK-MB levels in AMI patients showed an inverse relationship. Unlike CK-MB
levels which gradually increase in serum (within 3 - 8 hours) to peak at 18 hours, IMg
levels remain constant for 12 - 18 hours before falling rapidly. The maximum change
in IMg occurs within a short period of about 6 hours. As CK-MB returns to base line
levels in the next 48 hours, IMg levels also return to normal levels but more quickly,
within 3 0 -4 2 hours.

Figure 4.9
Mean serum concentrations of IMg and CK-MB of AMI patients.
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Figure 4.10 illustrates the inverse relationship between IMg and CK-MB, in AMI
patients.

Separating patients according to their CK-MB levels clearly identified a

decrease in IMg with CK-MB increases. AMI patients (n = 18) with only modest
increases in peak CK-MB (<25 pg/L), had mean IMg concentrations of 0.501 ± 0.063
mmol/L. AMI patients (n = 32) with CK-MB ranging from 25 - 100 pg/L, had mean
IMg concentrations of 0.474 ± 0.047 mmol/L. AMI patients (n = 13) with CK-MB
ranging from 100 - 200 pg/L, had mean IMg concentrations of 0.469 ± 0.043 mmol/L.
Those AMI patients (n = 9) with CK-MB ranging from 200 - >386 pg/L, had mean
IMg concentrations of 0.443 ± 0.024 mmol/L.

Figure 4.10
Proportional decrease in IMg to CK-MB increase.
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These findings led to the investigation for a relationship between CK-MB and IMg
concentrations. Figure 4.11 shows the scatter graph of the square root of CK-MB and
IMg concentrations of non-AMI patients. The square root transformation of CK-MB
concentrations was selected to achieve close approximations to normality, since the data
obtained was not normally distributed. The correlation coefficient was 0.066, which is
not statistically significant (P - 0.27). The linear equation was IMg = 0.522 - 0.011 x
(CK-MB). The non-AMI group shows a spread of points both horizontally (CK-MB)
and vertically (IMg) demonstrating poor correlation. The trend line indicates a slight
decreasing trend for IMg with increasing CK-MB. The lack of correlation indicated
that there is no relationship between serum IMg and CK-MB concentrations in
non-AMI patients.

Figure 4.11
Correlation between serum CK-MB and IMg concentrations of non-AMI patients.
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Figure 4.12 shows the scatter graph of the square root of CK-MB and IMg
concentrations of AMI patients.

By comparison, the trend line for AMI patients

indicates a decreasing trend for IMg with increasing CK-MB.

The correlation

coefficient was 0.383, which is statistically significant (P = 0.002). The linear equation
was IMg = 0.509 - 0.004 x (CK-MB).

The AMI group shows tight horizontal

clustering (CK-MB) with a spread of points vertically (IMg), resulting in a significant
correlation.

Figure 4.12
Correlation between serum CK-MB and IMg concentrations of AMI patients.
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4.3.6

Predictive value of IMg in the diagnosis of AMI.

It was apparent that the AMI group of patients could be distinguished from the non
AMI group on the differences in IMg. The 1 8 - 2 4 hour time interval, following the
onset of chest pain (Figure 4.9), was the period exhibiting the greatest statistical
difference in the mean IMg concentration between the AMI and non-AMI groups.
A cut-off point was selected rather than a reference range for the normal population as
overall IMg concentrations varied from patient to patient. For example, AMI patients
had decreases in IMg concentrations (at the 18 - 24 hour time interval) that were still
within the normal reference range.

In addition, low IMg concentrations were also

detected in patients without AMI. From the data, the best cut-off point at the 18 - 24
hour time interval was determined to be <0.47 mmol/L. This value allowed the highest
sensitivity, specificity and overall efficiency of IMg for predicting AMI.

The usefulness of applying this criterion to the data can be determined by calculating
the diagnostic sensitivity, specificity, predictive value and efficiency of the selection
rules. The sensitivity of the test is a measure of the frequency of a positive test when
AMI is present. Specificity is a measure of the frequency of a negative test when there
is no AMI present. The predictive value of the test is the frequency of AMI occurring in
those patients who have decreased IMg concentrations. The efficiency of a test indicates
the percentage of patients who have been correctly classified by the test result as having
or not having AMI (139). Table 4.3 shows the predictive value of IMg for diagnosing
AMI.
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Table 4.3
The predictive value of measuring IMg concentrations of <0.47 mmol/L in AMI.

Test

Number with
Positive
test results

Number with
Negative
test results

Total

AMI +

43

28

71

AMI“

26

65

91

Total

69

93

162

Sensitivity == 61%

Predictive value

Specificity == 71%

Efficiency of test = 67%

= 62%

Patients in which a diagnosis of AMI was established using traditional parameters.
Patients in which a diagnosis of AMI was excluded using traditional parameters.

In this application, 62% of the patients with low IMg had AMI. Overall, 67% of
patients were correctly classified as AMI or non-AMI by using IMg. The sensitivity
and specificity values indicated that IMg measurement correctly classified patients
within 61% of cases, and correctly eliminated AMI in normal individuals in 71% of
cases.

The current data indicate that the clinical sensitivity, specificity and the

predictive value of using serum IMg for the diagnosis of AMI are insufficient for
effective clinical diagnosis.
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4.4

Discussion

Biochemical markers, in particular CK-MB, have become the ‘gold standard’ for
diagnosis of AMI. For the diagnosis of AMI, the ideal biochemical test must have a
good clinical performance as indicated by the diagnostic sensitivity and specificity,
showing discrete separation between AMI and non-AMI patients. This study compares
for the first time the sequential quantitation of serum IMg and CK-MB for the detection
of myocardial cell death and damage due to AMI.

The results obtained in this study show that serum IMg levels in AMI patients drop
significantly (P <0.001) by 7.0% compared to initial values. This finding agrees with
those of Dyckner (46), Flink et al (58) and Rector et al (113) who reported a decrease of
serum magnesium of 4.7%, 6.2% and 11.2%, respectively. The non-AMI group had no
significant (P - 0.276) change in their IMg levels over the time monitored. Serum IMg
follows a characteristic fall and rise in those patients with AMI, which is inversely
related to the serum CK-MB over the same period.

The statistically significant

(P = 0.002) correlation (r = 0383) between CK-MB and IMg confirmed this relationship.

By using a cut-off value of <0.47 mmol/L, the predictive value (62%) of IMg for AMI
was low, with a sensitivity of 61% and a specificity of 71%, with an overall efficiency
of testing of 67%. These values are low when compared to CK-MB (sensitivity 91.5%,
specificity 97.4%). Nevertheless, the predictive usefulness of IMg may increase when
used in conjunction with other more conventional parameters such as the ECG.
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This study found no significant change in serum TMg concentrations in both AMI
(P 0.996) and non-AMI (P - §597) patients within the monitoring period. This finding
agrees with other reports (45, 82, 100, 151) that found no significant change in serum
TMg concentrations in patients with AMI.

Serum TMg concentrations remained

constant with little fluctuation throughout the time monitored. Overall, the serum TMg
concentrations of both groups remained within the normal reference range.

Although different studies (2, 14, 34, 35, 46, 58, 66, 72, 113) report that a decrease in
serum magnesium occurs in acute ischaemia, this is not a universal finding.
Controversy exists because other studies report normal (45, 82, 100, 151) and even
raised (41, 48) serum magnesium concentrations. From the data in this study, it seems
likely that hypomagnesaemia associated with AMI may only be transient, and serum
IMg levels may fluctuate with ischaemic events. This suggests that the time intervals
used for obtaining blood samples from AMI patients in previous studies were too broad
to measure such rapid fluctuations. The time lag between the onset of myocardial
infarction and determination of magnesium varies from several hours after admission to
the hospital to two weeks after infarction.

Dyckner (46) observed a decrease in

magnesium levels in samples collected less than 24 hours after the onset of AMI. Ebel
et al (48), on the other hand, reports of studies that have obtained normal magnesium
concentrations 24 to 72 hours after the acute event. Therefore, if the samples were
taken late in the course of the disease, the magnesium levels may well have returned to
normal. Another reason why the role of magnesium in myocardial infarction has been
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inadequately defined is that, with few exceptions, the majority of studies to date have
focused on TMg and not the biologically active fraction, IMg.

There are several theories to explain the changes in serum magnesium concentration
after myocardial infarction. One explanation is that, several hours after myocardial
infarction, the IMg released from infarcted areas of the heart lead to a transient increase
in serum magnesium levels. Experimentally induced myocardial infarction has shown
that there is an immediate efflux of magnesium from the ischaemic area into the blood
from the coronary sinus (48, 108). The magnesium content of the necrotic area drops
by up to 30% during the first hour. However, as pre-infarction magnesium levels are
usually not known, this initial rapid rise may be overlooked. Subsequently, less than 24
hours after myocardial infarction, magnesium levels may decrease due to an increased
renal loss following the secretion of catecholamines, i.e. adrenaline and noradrenaline
(149).

Other explanations for the post-infarction decrease in serum magnesium are also
possible. Flink et al (58) investigated the correlation between decreased magnesium
levels and an increase in fatty acids following AMI. The rise in free fatty acid levels is
due to an increase in lipolysis induced by a rise in increased catecholamine secretion as
a result of the infarct. Since free fatty acids bind with magnesium, it has been assumed
that the overall serum magnesium levels are reduced.
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Another explanation for the lowering of serum magnesium during increased lipolysis is
the increased binding of magnesium by free fatty acids within adipocytes (i.e. cells that
store fat). Adrenaline has been shown to increase magnesium uptake by these cells.
Ebel et al (48) reports that this small increase in magnesium intake by adipose tissue is
sufficient to produce the small decreases (4.7% to 11.2%) observed in magnesium
levels.

Therefore, due to different amounts of adipose tissue and catecholamine

secretion among individuals, the decrease in serum magnesium might differ from
patient to patient.

In conclusion, the data presented here show that the measurement of serum IMg levels
is a better indicator of magnesium status, than serum TMg, in patients with AMI.
Although AMI patients were found to have a characteristic pattern of fall and rise in
their serum IMg levels, it was determined that the measurement of serum IMg alone is
not diagnostic for AMI.

From the theories outlined above, the decrease in serum

magnesium levels in AMI is uncertain and may be a secondary phenomenon.
Nevertheless, serum IMg levels may be used as an additional clinical tool for
assessment of myocardial injury, along side CK-MB and ECG recordings.
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C hapter 5 Su m m a r y a nd
CLINICAL IMPLICATIONS

Chapter 2 of this thesis aimed to verify previous precision studies on the AVL 988-4
IMg ISE. Previous studies based their estimates of instrument precision on the results
from protein-based solutions. These may not reflect the true performance of the IMg
ISE with clinical samples.

The inclusion of serum samples to determine analyser

precision was one improvement in this study. The within-run and day-to-day precision
were determined to be <2.30% and <2.81%, respectively. From this study it was
concluded that the AVL IMg ISE was suitable for patient monitoring.

Chapter 3 was aimed at determining the effect of duration and temperature of storage on
the stability of IMg in clinical samples. A comparison was also made between serum
and whole blood to determine if both sample types were acceptable for IMg analysis.
Both sample types have their advantages under certain clinical situations. From this
study it was concluded that whole blood samples were only acceptable for IMg analysis,
if stored for less than 3 hours at 4 °C. Serum samples were acceptable for IMg analysis
up to 7 days of storage at -20 °C. Furthermore, it was determined that there is no
significant (P = 0.674) difference in IMg concentration by using either whole blood or
serum samples. Under urgent conditions the use of whole blood samples would result
in much quicker turnaround times. On the other hand, serum has its advantages in that
it can be stored for longer periods for batch analysis.

Following on from the results of Chapters 2 and 3 it was possible to reliably and
confidently determine and monitor serum IMg levels. The final objective of this study
was to determine if IMg concentrations in the AMI group differed from the non-AMI
group. It should be noted that a study of this type, aimed at monitoring the serum levels
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of EMg and CK-MB in non-AMI and AMI patients, has not been previously done.
Altogether, serum CK-MB, TMg and IMg concentrations of AMI patients were
monitored for up to 66 hours after the onset of chest pain. Identical measurements were
made in non-AMI patients. The AMI group elicited the characteristic pattern of rise and
fall in CK-MB, whereas non-AMI patients showed no change. Over the same period,
TMg concentrations remained constant in both the non-AMI and AMI groups, with no
significant (P = 0.996) changes observed in the AMI group throughout the 66 hours of
study. On the other hand, IMg concentrations decreased significantly (P <0.001) by
7.0% in the AMI group, at the 18 - 24 hour time interval.

No change in IMg

concentration was detected in the non-AMI patients over the same period.

These findings led to the investigation for a relationship between CK-MB and IMg
levels. The correlation (r=0383) between CK-MB and IMg was statistically significant
(P - 0.002), though too low to be of clinical use on its own. The predictive value (62%)
of measuring IMg in patients with AMI was also low (sensitivity 61% and specificity
71%), with an overall efficiency of testing of 67%, but did not preclude its use as a
diagnostic test in assessing patients with AMI.

C hapter 5 - S um m ary a n d clinical implications

Page 90

Clinical implications
The diagnosis of massive AMI is generally based on clinical symptoms and ECG
recordings.

In these patients biochemical assays generally serve to confirm this

diagnosis (77, 94, 97, 140). Only a minority of patients with chest pain, however, has
clear evidence for AMI on ECG recordings. In the vast majority, the ECG is normal or
reveals non-specific changes of the ST segment or T wave only. The exclusion of acute
myocardial cell damage in this large group of patients depends entirely on biochemical
tests such as CK-MB.

Since magnesium has been reported by numerous authors to decrease in patients with
AMI, to facilitate the biochemical detection for acute myocardial cell necrosis, this
study attempted to determine if IMg could be used as a diagnostic tool for the detection
of myocardial infarction.

Measurement of IMg, rather than TMg, gave a better

indication of magnesium status, especially in circumstances where magnesium
supplements need to be administered. One major advantage of determining IMg in
patients with a very high probability of AMI is the cost effectiveness, convenience and
ease of testing.

It allows an almost instantaneous analysis of clinical findings,

biochemical test results and ECG recordings at the patient’s bedside.

In conclusion, the results obtained from this study show that IMg alone may not provide
a definitive diagnosis of myocardial damage.

Measurement of IMg concentrations

along with other parameters, such as ECG recordings, may improve the predictive value
of IMg for the diagnosis of AMI.
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A p p e n d ix A C o nsent fo r m

I L L A W A R R A

PATHCENTRE
A Facility of the lllawarra Area Health Service

lllawarra Regional Hospital
Wollongong Campus
P.O .Box 1798
Wollongong NSW 2500

EXT:
YOUR REF:
OUR REF:

Telephone: (042) 29 8233
Facsimile: (042) 20 1514

Measurement of ionised magnesium in patients with
CARDIOVASCULARDISEASE
The Biochemistry Department of the lllawarra Pathcentre in conjunction with Dr Dwain
Owensby of the Cardiology Department are assessing ionised magnesium levels in patients with
cardiovascular disease. Magnesium deficiency has been implicated as a causative agent in
atherogenesis and cardiovascular disease. This research may help in the understanding of the
pathogenesis of ischaemic heart disease and cardiovascular events.
We are asking for patients who attend the Coronary Care Unit and the Accident and Emergency
Department of the lllawarra Regional Hospital, Wollongong Campus to have blood collected on
admission to the Unit. Healthy aged and sex matched pairs of volunteers will also have blood
collected for ionised whole blood magnesium level.
If you agree to participate in this study, your results will be reported as data only and you will
not be identified in any way.
If you have queries regarding any aspect of this research project, please contact Dr Owensby
Director of Cardiology at the lllawarra Regional Hospital on (042) 201 279 or Ms Karen
McRae, Research Office, Administration, University of Wollongong NSW 2500. You have the
right to withdraw from this study at any time without prejudice.

CONSENT FORM
The aims of this project is to monitor magnesium levels in normal patients and patients admitted
to Coronary Care Unit. This has been explained to me and I consent to be included in this study.
NAME: (please print)
SIGNATURE_______________________ DATE
WITNESS_______________________________
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A p p e n d ix B C o l l e c t io n p r o t o c o l

C o l l e c t io n P r o t o c o l

Before collecting blood ensure a consent form has been completed and signed.

COLLECTING PROCEDURE: (Using supplied Sarstedt Monovette syringe system).

1. Replace the orange cap of a sterile Monovette syringe system with the supplied
needle adaptor (Do not discard orange cap).
2. Secure needle by twisting clockwise.
3. Puncture vein and withdraw plunger slowly until sufficient blood (approx. 2 mL) is
collected. Wait until blood flow stops.
4. Remove Monovette from the needle by twisting anticlockwise. (Needle remains in
vein) and complete blood collection by withdrawing needle from vein.
5. Cap Monovette syringe by securing the original orange cap.
Monovette base and break off plunger.
6.

Lock piston into

Mix sample thoroughly.

7. Affix label to the Monovette syringe with patient’s:
- Name
- MRN
-DOB
-Ward
- Time and Date of collection
8.

The sample now needs to be taken to the Biochemistry Department as soon as
possible for immediate analysis. During transit, keep the sample at room
temperature. Do not store on ice.

Note: Please do not transfer blood from another type of tube to the Monovette
syringe.

A p p e n d ix

b

- C o l l e c t io n

pro to co l

Page 95

B ib l io g r a p h y

1.

Abraham, A. Treatment of patients with acute myocardial infarction with

intravenous magnesium. Mag TrElem 9: 177-185, 1990.

2.

Abraham, A., U. Eylath, M. Weistein, and E. Czaczkes. Serum magnesium

levels in patients with acute myocardial infarction. N Engl J Med 296: 862,
1977.

3.

Adams, J., G. Bodor, V. Davila-Roman, J. Delmez, F. Apple, J. Ladenson,
and A. Jaffe. Cardiac Troponin I: A marker with high specificity for cardiac

injury. Circulation 88: 101-106, 1993.

4.

Adams, J., K. Schechtman, and Y. Landt. Comparable detection of acute

myocardial infarction by creatine kinase MB isoenzyme and cardiac troponin I.
Clin Chem 40: 1291-1295, 1994.

5.

Agus, Z., and M. Morad. Modulation of cardiac ion channels by magnesium.

Ann Rev Physiol 53: 299-307, 1991.

6.

Agus, Z., A. Wasserstein, and S. Goldfarb. Disorders of calcium and

magnesium homeostasis. Am J Med 72: 473-488, 1982.

7.

Alberts, B., D. Bray, J. Lewis, M. Raff, K. Roberts, and J. Watson.

Molecular biology o f the cell. New York: Garland Publishing, Inc, 1994.

8.

Altura, B., and B. Altura. Ionised magnesium measurements in serum, plasma

and whole blood in health and disease. In: Advances in magnesium research: 1
Magnesium in Cardiology, edited by R. Smetana. London: John Libbey and
Company, 1997, p. 538-546.
9.

Altura, B., and B. Altura. Magnesium and cardiovascular diseases. In:

Handbook o f Metal-ligand interactions in biological fluids (Bioinorganic
Fluids), edited by G. Berthon. New York: Marcel Dekker Inc, 1995, p. 822-842.
B ib l io g r a p h y

Page 97

10.

Altura, B., and B. Altura. Magnesium in cardiovascular biology. Scientific

American: Science and Medicine : 28-37, 1995.

11.

Altura, B., and B. Altura. Magnesium metabolism, atherogenesis and

cardiovascular pathobiology. In: Advances in magnesium research: 1 Magnesium
in Cardiology, edited by R. Smetana. London: John Libbey and Company Ltd,
1997, p. 28-37.

12.

Altura, B., and B. Altura. Measurement of ionised magnesium in whole blood,

plasma and serum with a new ion-selective electrode in healthy and diseased
human subjects. Magnesium Trace Elements 10: 90-98, 1992.

13.

Altura, B., and B. Altura. New perspectives on the role of magnesium in the

pathophysiology of the cardiovascular system. II Experimental aspects.
Magnesium 4: 245-271, 1985.

14.

Altura, B., and B. Altura. New perspectives on the role of magnesium in the

pathophysiology of the cardiovascular system: I Clinical aspects. Magnesium 4:
226-244, 1985.

15.

Altura, B., and B. Altura. Role of magnesium in the pathogenesis of

hypertension: Relationship to its actions on cardiac, vascular smooth muscle,
and endothelial cells updated. In: Hypertension: Pathophysiology, Diagnosis,
and Management (2nd ed.), edited by a. B. B. JH Laragh. New York: Raven
Press, 1995, p. 1213-1242.

16.

Altura, B., B. Altura, A. Gesowalt, H. Ising, and T. Gunther. Magnesium

deficiency and hypertension: correlations between magnesium deficient diets
and microcirculatory changes in situ. Science 223: 1315-1318, 1984.

B ib l io g r a p h y

Page 98

17.

Altura, B., F. Bertschat, A. Jeremias, H. Ising, and B. Altura. Comparative

findings on serum IMg of normal and diseased human subjects with the NOVA
and KONE ISE’s for Mg. Scand J Clin Lab Invest 54: 77-81, 1994.

18.

Altura, B., T. Shirey, C. Young, K. Dell’Orfano, J. Hiti, R. Welsh, Q. Yeh,
R. Barbour, and B. Altura. Characterization of a new ion selective electrode

for ionised magnesium in whole blood, plasma, serum, and aqueous samples.
Scand J Clin Lab Invest 54: 21-36, 1994.

19.

Andre-Fouet, X., M. Pillot, A. Leizorovicz, G. Finet, C. Gayet, and H.
Milon. 'Non-Q-wave' alias 'nontrasmural' myocardial infarction: a specific

entity. Am Heart J 117: 892-902, 1989.

20.

Antman, E. Randomised trials of magnesium in acute myocardial Infarction:

Big numbers do not tell the whole story. Am J Cardiol 75: 391-393, 1995.

21.

Antman, E., M. Tanasijevic, and C. Cannon. Cardiac troponin I on admission

predicts death by 42 days in unstable angina and improved survival with early
invasive strategy: Results from TIMI TUB. Circulation (suppl) 92: 604, 1995.

22.

Apple, F. Measurement of cardiac troponin-I in serum for the detection of

myocardial infarction. JIntF ed Clin Chem 8: 148-150, 1996.

23.

Apple, F., M. Rogers, and W. Sherman. Profile of creatine kinase isoenzymes

in skeletal muscles of marathon runners. Clin Chem 30: 413-416, 1984.

24.

Arsenian,

M.

Magnesium

and

cardiovascular

disease.

Progress

in

Cardiovascular Diseases 35: 271-310, 1993.

25.

Aukawa, J. Magnesium: its biological significance. New York: CRS Press Inc.,

1981.

B ib l io g r a p h y

Page 99

26.

Balkin, J. The use of magnesium in critical coronary care patients. Management

of cardiac arrhythmias. In: Advances in Magnesium research, edited by
R. Smetana. London: John Libbey and company Ltd, 1997, p. 21-27.

27.

Balogh, I., M. Berenyi, T. Fazekas, Z. Janka, S. Kiss, Z. Kiss, G. Koppany,
G. Kovacs, M. Kovacs, K. Gaal-Kovacs, B. Lakatos, J. Loch, and J.
Lonovics. Magnesium in biological systems: environmental and biochemical

aspects, edited by T. Fazekas, B. Selmeczi and P. Stefanovits. Budapest:
Akademiai Kiado, 1994.

28.

Baxter, G., M. Sumeray, and J. Walker. Infarct size and magnesium: insight

into LIMIT-2 and ISIS-4 from experimental studies. Lancet 348: 1424-1426,
1996.

29.

Baxter, J. The use of magnesium in critical care patients. Management of

cardiac arrhythmias. In: Advances in magnesium research: 7, edited by
R. Smetana. London: John Libbey, 1997, p. 21-27.

30.

Bernstein, L., E. Sachs, and A. Jonas. Timed sequential measurements of

creatine kinase MB in diagnosis of myocardial infarction. Clin Chem 30:
1588-1589, 1984.
31.

Beyenbach, K. Transport of magnesium across biological membranes.

Mag TrElem 9: 233-254, 1990.

32.

Black, C., and J. Cowan. Magnesium dependent enzymes in general

metabolism. In: The biological chemistry o f magnesium, edited by J. Cowan.
Columbus OH: VCH Publishers, Inc, 1995, p. 159-183.

33.

Bloom, S. Myocardial injury in magnesium deficiency. In: Magnesium in health

and disease, edited by Y. Itokawa and J. Durlach. London: John Libbey and
Company Ltd, 1989, p. 191-197.
B ib l io g r a p h y

Page 100

34.

Bogdan, M., E. Nartowicz, and M. Ukleja-Adamowicz. Serum concentrations

and erythrocyte contents of magnesium, potassium and sodium in patients with
acute myocardial infarction. In: Advances in magnesium research: 1 Magnesium
in cardiology, edited by R. Smetana. London: John Libbey and Company, 1997,
p. 52-57.

35.

Borchgrevink, P., A. Bergan, O. Bakoy, and P. Jynge. Magnesium and

reperfusion of ischemic rat heart as assessed by 31P-NMR. Am J Physiol
256: H195-H204, 1989.

36.

Brookes, C., and C. Fry. Ionised magnesium and calcium in plasma from

healthy

volunteers

and

patients

undergoing

cardiopulmonary

bypass.

Br Heart J 69: 404-408, 1993.

37.

Burch, G., and T. Giles. The importance of magnesium deficiency in

cardiovascular disease. Am Heart J 94: 649-657, 1977.

38.

Carlier, P., C. Wary, P. Jehenson, and G. Bloch. Magnesium content in

plasma and erythrocytes is uncorrelated with brain and muscle free intracellular
concentrations as determined in vivo by 3 IP NMR spectroscopy. In: Current
research in magnesium, edited by M. Halpem and J. Durlach. London: John
Libbey and Company, 1996, p. 25-26.

39.

Ceremuzynski, L., R. Jurgiel, P. Kulakowski, and J. Gebalska. Threatening

arrhythmias in acute myocardial infarction are prevented by intravenous
magnesium sulfate. Am Heart J 118: 1333-1334, 1989.

40.

Chipperfield, B., and J. Chipperfield. Differences in metal content of the heart

muscle in death from ischaemic heart disease. Am Heart J 95: 732-737, 1978.

B ib l io g r a p h y

Page 101

41.

Chipperfield, B., and J. Chipperfield. Relation of myocardial metal

concentrations to water hardness and death rates for ischemic heart disease.
Lancet ii: 709-712, 1979.

42.

Davidson, J., D. Emslie-Smith, M. Fulton, R. Kellet, A. Lorimer, K. Lowe,
J. McGuinness, D. Maclean, G. McNeill, H. Miller, D. Ross, G. Shaw, M.
Walker, W. Walker, and H. Watson. The new medicine. Boston: MTP Press

Ltd, 1983.

43.

Delva, P., C. Pastori, M. Degan, M. Montesi, and A. Lechi. Intralymphocyte

divalent cations in essential hypertensive patients. In: Current research in
magnesium, edited by M. Halpem and J. Durlach. London: John Libbey and
Company Ltd, 1996, p. 45-47.

44.

Drakenberg, T. Physical methods for studying the biological chemistry of

magnesium. In: The biological chemistry o f magnesium, edited by J. A. Cowan.
Columbus: VCH Publishers, Inc., 1995, p. 25-50.

45.

Durak, I., A. Sahin, Z. Yurtarslanj, and A. Sonel. Analysis of calcium, zinc,

magnesium, iron and copper content in myocardium and stenotic mitral valve.
Am J Cardiol 64: 1392-1394, 1989.

46.

Dyckner, T. Serum magnesium in acute myocardial infarction: Relation to

arrhythmias. Acta Med Scand 207: 59-66, 1980.

47.

Dyckner, T., and P. Wester. Effect of magnesium on blood pressure.

B rM ed J 286: 1847-1849, 1983.
48.

Ebel, H., and T. Gunther. Role of magnesium in cardiac disease. J Clin Chem

Clin Biochem 21: 249-265, 1983.

B ib l io g r a p h y

Page 102

49.

Eisenberg, M. Magnesium deficiency and sudden death. Am Heart J 124: 544

549, 1992.

50.

Elm, R. Evaluating the role of ionized magnesium in laboratory and clinical

practice. In: Advances in magnesium research: 1, edited by R. Smetana.
London: John Libbey and Company Ltd, 1997, p. 525-531.

51.

Elin, R. Recent advances in the determination of ionized magnesium.

Clin Chem 39: 1330, 1993.

52.

Elin, R., E. Hristova, S. Cecco, J. Niemela, and N. Rehak. Comparison of the

AVL and NOVA magnesium ion-selective electrodes for precision and effect by
pH and calcium. 15th International Symposium on Blood Gases and pH,
electrolytes and other critical analytes, Sweden, 1994, p. 1-20.

53.

Eugster, R., B. Rusterholz, A. Schimd, U. Spichiger, and W. Simon.

Characterization procedure for ion-selective electrode assays of magnesium
activity in aqueous solutions of physiological composition. Clin Chem 39:
855-859, 1993.
54.

Filos, D., J. Petersen, and A. Okorodulu. ISE method for determining ionised

magnesium in biological specimens. Clin Chem 39: 1177, 1993.

55.

Flatman, P. Magnesium and ion transport in red cells. In: Magnesium in health

and disease, edited by Y. Itokawa and J. Durlach. London: John Libbey and
Company Ltd, 1989, p. 43-51.
56.

Flatman, P. Mechanisms of magnesium transport. Ann Rev Physiol 53:

259-271, 1991.

B ib l io g r a p h y

Page 103

57.

Flink, E. Magnesium deficiency and magnesium toxicity in man. In: Trace

elements in human health and disease: Volume II Essential and toxic elements,
edited by A. Prasad and D. Oberleas. London: Academic Press, 1976, p. 1-21.

58.

Flink, E., J. Brink, and S. Shane. Alterations of long-chain free fatty acids and

magnesium concentrations in acute myocardial infarction. Arch Intern Med 141:
441-443, 1981.

59.

Galloe, A.,

and N. Graudal. Magnesium and myocardial infarction.

Lancet 343: 1286-1287, 1994.

60.

Galvani, M., F. Ottani, and J. Ladenson. Adverse influence on elevated

cardiac troponin I in unstable angina. Circulation (suppl) 92:1-663, 1995.

61.

Gasser, R. Free intracellular magnesium during myocardial ischaemia: the state

of the art. In: Advances in magnesium research: 1, edited by R. Smetana.
London: John Libbey and Company Ltd, 1997, p. 103-110.

62.

Gibler, W., G. Young, J. Hedges, L. Lewis, M. Smith, S. Carleton, R.
Aghababian, R. Jorden, E. J. Allison, and E. Often. Acute myocardial

infarction in chest pain patients with nondiagnostic ECGs: serial CK-MB
sampling in the emergency department: the Emergency Medicine Cardiac
Research Group. Annals o f Emergency Medicine 21: 504-512, 1992.

63.

Gunzel, D., and W. Schlue. Interactions between magnesium, sodium and

intracellular pH in leech Retzius neurones. In: Advances in magnesium
research: 1 magnesium in cardiology, edited by R. Smetana. London: John
Libbey and Company Ltd, 1997, p. 497-506.

64.

Hall, S., and C. Fry. Magnesium affects excitation, conduction, and contraction

of isolated mammalian cardiac muscle. Am J Physiol 32: H622-H633, 1992.

B ib l io g r a p h y

Page 104

65.

Halpern, M., S. Llobet, C. Monteiro, and J. Carvalho Rodrigues. Ionised

magnesium determination: storage conditions, precision studies and reference
values. In: Current research in magnesium, edited by M. Halpem and J.
Durlach. London: John Libbey and Company Ltd, 1996, p. 5-6.

66.

Headrick, J., and R. Willis. Cytosolic [Mg2+] in simulated hypoxic, or

ischaemic rat heart. J Molec Cell Cardiol 21: S40, 1989.

67.

Herzog,

W.,

and

D.

Atar.

Magnesium

and myocardial

infarction.

Lancet 343: 1285-1286, 1994.

68.

Horie, M. Role of intracellular magnesium ion in the regulation of mammalian

cardiac potassium channels. In: Magnesium in health and disease, edited by Y.
Itokawa and J. Durlach. London: John Libbey and Company Ltd, 1989,
p. 35-42.

69.

Horner, S. Efficacy of intravenous magnesium in acute myocardial infarction in

reducing arrhythmias and mortality. Meta-analysis of Magnesium in Acute
Myocardial Infarction. Circulation 86: 774-779, 1992.

70.

Horner, S. Magnesium and myocardial infarction. Lancet 343: 1287, 1994.

71.

Hristova, E., S. Cecco, J. Niemela, N. Rehak, and R. Elin. Analyzer-

dependent differences in results for ionized calcium, ionized magnesium,
sodium, and pH. Clin Chem 41: 1649-1653, 1995.

72.

Hughes, A., and R. Tonks. Platelets, magnesium, and myocardial infarction.

Lancet 1: 1044-1046, 1965.
73.

Irvin, R., F. Cobb, and C. Roe. Acute myocardial infarction and MB creatine

phosphokinase. Arch Intern Med 140: 329-334, 1980.

B ib l io g r a p h y

Page 105

74.

Iseri, L., and J. French. Magnesium: Nature's physiologic calcium blocker.

Am Heart J 108: 188-193, 1984.

75.

ISIS-4 (Forth International Study of Infarct Survival) Collaborative Group.

ISIS-4: a randomised factorial trial assessing early oral captopril, oral
mononitrate, and intravenous magnesium sulphate in 58 050 patients with
suspected acute myocardial infarction. Lancet 345: 669-685, 1995.

76.

ISIS-4 Collaboration Group. Fourth International Study of Infarct Survival:

Protocol for a large simple study of the effects of oral mononitrate, of oral
captopril, and of intravenous magnesium. Am J Cardiol 68: 87D-100D, 1991.

77.

Jablonsky, G., F. Leung, and A. Henderson. Changes in LD1/LD2 ratio

during the first day after myocardial infarction. Clin Chem 31: 1621-1624, 1985.

78.

Kafka, H., L. Langevin, and P. Armstrong. Serum magnesium and potassium

in acute myocardial infarction. Arch Intern Med 147: 465-469, 1987.

79.

Kaplan, L., and A. Pesce. Clinical chemistry: theory, analysis, and correlation.

St Louis: The C.V. Mosby Company, 1989.

80.

Kazda, A., P. Stern, H. Nekvasilova, and J. Hendl. Relationship of

magnesium and selected biochemical parameters in clinical practice. In:
Advances in magnesium research: 1 Magnesium in cardiology, edited by R.
Smetana. London: John Libbey and Company Ltd, 1997, p. 547-552.

81.

Keshgegian, A., and N. Feinberg. Serum creatine kinase MB isoenzyme in

chronic muscle disease. Clin Chem 30: 575-578, 1984.

B ib l io g r a p h y

Page 106

82.

Knochel, J. Disorders of magnesium metabolism. In: Harrison's principles o f

internal medicine (14ed.), edited by D. Kasper, S. Hauser, D. Longo, E.
Braunwald, K. Isselbacher, J. Martin and A. Fauci. New York: McGraw-Hill
Inc., 1998, p. 2263-2266.

83.

Lareau, S., A. Boyle, R. Deslauriers, W. Keon, T. Kroft, and R. Labow.

Magnesium enhances function of postischaemic human myocardial tissue.
Cardiovascular Research 27: 1009-1014, 1993.

84.

Lareau, S., A. Boyle, L. Stewart, R. Deslauriers, P. Hendry, W. Keon, and
R.

Labow.

The

role

of

magnesium

in

myocardial

preservation.

Magnesium Research 8: 85-97, 1995.

85.

Larue,

C.,

C.

Calzolari,

and

J.Bertinchant.

Cardiac-specific

immunoenzymometric assay of troponin-I in the early phase acute myocardial
infarction. Clin Chem 39: 972-979, 1993.

86.

Lasserre, B. Magnesium and heart failure: an update. Where do we stand?

Where do we go? In: Advances in magnesium research: 7, edited by R. Smetana.
London: John Libbey and company Ltd, 1997, p. 12-20.

87.

Lasserre, B., M. Spoerri, V. Moullet, and M. Theubet. Should magnesium

therapy be considered for the treatment of coronary heart disease? II.
Epidemiological evidence in outpatients with and without coronary heart
disease. Magnesium Research 7: 145-153, 1994.

88.

Lauler, D. Magnesium-coming of age. Am J Cardiol 63: 1G-3G, 1989.

89.

Laurant,

P.,

J.

Kantelip,

and

A.

Berthelot. Dietary

magnesium

supplementation modifies blood pressure and cardiovascular function in
mineralocorticoid-salt hypertensive rats but not in normotensive rats. Journal o f
Nutrition 125: 830-841, 1995.
B ib l io g r a p h y

Page 107

90.

Lehninger, A. Principles o f biochemistry. New York: Worth Publishers, Inc.,

1982.

91.

Lim, P., and E. Jacob. Magnesium deficiency in patients on long-term diuretic
therapy for heart failure. Br Med J 3: 620-622, 1972.

92.

London, R. Methods of measuring intracellular magnesium: NMR and

fluorescence. Ann Rev Physiol 53: 241-258, 1991.

93.

Ludi, H., and H. Schatzmann. Some properties of a system for sodium-

dependent outward movement of magnesium from metabolizing human red
blood cells. J Physiol 390: 367-282, 1987.

94.

Mair, J., E. Artner-Dworzak, P. Lechleitner, J. Smidt, R. Eagner, F.
Dienstl, and B. Puschendorf. Cardiac troponin T in diagnosis of acute

myocardial infarction. Clin Chem 37: 845-852, 1991.

95.

Marsoner, H., U. Spichiger, C. Ritter, C. Sachs, M. Ghahramani, H.
Offenbacher, H. Kroneis, C. Kindermans, and M. Dechaux. Measurement of

ionized magnesium with neutral carrier based ISE's. Progress and results with
the AVL 988-4 magnesium analyzer. Scand J Clin Lab Invest 54: 45-51, 1994.

96.

Matsuda, H., A. Saigusa, and H. Irisawa. Clinic conductance through the

inwardly rectifying K channel and blocking of internal magnesium.
Nature 325: 156-159, 1987.
97.

McComb, J., E. McMaster, G. MacKenzie, and A. Adgey. Myoglobin and

creatine kinase in acute myocardial infarction. Br Heart J 51: 189-194, 1984.

98.

Mclean, R. Magnesium and its therapeutic uses: A Review. A m J Med

96: 63-76, 1994.

B ib l io g r a p h y

Page 108

99.

Meissner, G., and J. Henderson. Rapid calcium release from cardiac

sarcoplasmic reticulum vesicles is dependent on calcium and is modulated by
magnesium, adenine nucleotide, and calmodulin. J Biol Chem 262: 3065-3073,
1987.

100.

Miyagi, H., H. Yasue, K. Okumura, H. Ogawa, K. Goto, and S. Oshima.

Effects of magnesium on anginal attack induced by hyperventilation in patients
with variant angina. Circulation 79: 597-602, 1989.

101.

Muller, A., D. Gunzel, and W. Schlue. Stoichiometry of sodium/magnesium

antiport in leech Retzius neurones. In: Advances in magnesium research: 1
Magnesium in cardiology, edited by R. Smetana. London: John Libbey and
Company Ltd, 1997, p. 507-513.

102.

Murphy, E., C. Freudenrich, and M. Lieberman. Cellular magnesium and

Na/Mg exchange in heart cells. Ann Rev Physiol 53: 273-287, 1991.

103.

Oesch, U., D. Ammann, and W. Simon. Ion-selective membrane electrodes for

clinical use (Review). Clin Chem 32: 1448-1459, 1986.

104.

Ott, P., and P. Fenster. Should magnesium be part of the routine therapy for

acute myocardial infarction? Am Heart J 124: 1113-1118, 1992.

105.

Polancic, J. Magnesium: Metabolism, clinical importance, and analysis.

Clin Lab SciA\ 105-109, 1991.

106.

Potkin, R., J. Werner, G. Trobaugh, C. Chestnut, C. Carrico, A. Hallstrom,
and L. Cobb. Evaluation of noninvasive tests of cardiac damage in suspected

cardiac contusion. Circulation 66: 627-631, 1982.

B ib l io g r a p h y

Page 109

107.

Raju, B., E. Murphy, L. Levy, R. Hall, and R. London. A fluorescent

indicator for measuring cytosolic free magnesium. Am J Physiol 256:
C540-C548, 1989.

108.

Rasmussen, S., P. Aurup, S. Hojberg, K. E. Jensen, and P. McNair.

Magnesium and acute myocardial infarction: Transient hypomagnesemia not
induced by renal magnesium loss in patients with acute myocardial infarction.
Arch Intern Med 146: 872-874, 1986.

109.

Rasmussen, S., P. Norregard, O. Lindeneg, P. McNair, V. Backer, and S.
Balslev. Intravenous magnesium in acute myocardial infarction. Lancet :
234-236, 1986.

110.

Rayssiguier, Y., and A. Mazur. Metal ions and lipid metabolism. In: Handbook

o f Metal-ligand interactions in biological fluids (Bioinorganic Fluidsf edited by
G. Berthon. New York: Marcel Dekker Inc, 1995, p. 858-870.

111.

Rayssiguier, Y., A. Mazur, P. Cardot, and E. Gueux. Effects of magnesium

on lipid metabolism and cardiovascular disease. In: Magnesium in health and
disease, edited by Y. Itokawa and J. Durlach. London: John Libbey and
Company Ltd, 1989, p. 199-207.

112.

Rayssiguier, Y., A. Mazur, E. Gueux, and E. Rock. Magnesium deficiency

affects lipid metabolism and atherosclerosis process by a mechanism involving
inflammation and oxidative stress. In: Current research in magnesium, edited by
M. Halpem and J. Durlach. London: John Libbey and Company, 1996,
p. 251-255.
113.

Rector, W., M. DeWood, and R. Williams. Serum magnesium and copper

levels in myocardial infarction. Am J Med Sci 281: 25-29, 1981.

B ib l io g r a p h y

Page 110

114.

Rehak, N., S. Cecco, J. Niemela, E. Hristova, and R. Elin. Linearity and

stability of the AVL and Nova magnesium and calcium ion-selective electrodes.
Clin Chem 42: 880-887, 1996.

115.

Reinhart, R. Clinical correlates of the molecular and cellular actions of

magnesium on the cardiovascular system. Am Heart J 121: 1513-1521, 1991.

116.

Reyes, A. Magnesium and diuretics: 10 years of progress. In: Current research

in magnesium, edited by M. Halpem and J. Durlach. London: John Libbey and
Company, 1996, p. 293-295.

117.

Romani, A., and A. Scarpa. Regulation of cell magnesium. Arch Biochem

Biophys 298: 1-12, 1992.

118.

Rude, R. Physiology of magnesium metabolism and the important role of

magnesium in potassium deficiency. Am J Cardiol 63: 31G-34G, 1989.

119.

Rude, R,, W. Poole, J. Muller, Z. Turi, J. Rutherford, R. Roberts, D. Raabe,
H. Gold, P. Stone, J. Willerson, E. Braunwald, and M. S. Group.

Electrocardiographic and clinical criteria for recognition of acute myocardial
infarction based on analysis of 3,697 patients. Am J Cardiol 52: 936-942, 1983.

120.

Ryan, M. Diuretics and potassium/magnesium depletion. Am J Med 82: 38-46,

1987.

121.

Sachs, C., H. Marsoner, C. Ritter, C. Kindermans, and M. Ghahramani.

Ionised magnesium measurement in serum. Clin Chem 39: 1176, 1993.

122.

Saito, N., S. Nishiyama, T. Okada, Y. Konishi, M. Shirota, and H.
Takatsuji. The role of magnesium in preventing vascular complications. In:

Current research in magnesium, edited by M. Halpem and J. Durlach. London:
John Libbey and Company Ltd, 1996, p. 33-38.
B ib l io g r a p h y

Page 111

123.

Schroll, A. Importance of magnesium for the electrolyte homeostasis- an

overview. In: Advances in magnesium research: 1, edited by R. Smetana.
London: John Libbey and Company Ltd, 1997, p. 463-472.

124.

Sebekova, K., K. Stefikova, V. Spustova, I. Lajdova, and R. Dzurik. 3IP

NMR spectroscopy investigation of free magnesium concentration and
intracellular pH in skeletal muscle of patients with essential hypertension with or
without insulin resistance. In: Current research in magnesium, edited by M.
Halpem and J. Durlach. London: John Libbey and Company, 1996, p. 21-23.

125.

Sebekova, K., K. Stefikova, V. Spustova, V. Mlynarik, I. Tkac, and R.
Dzurik. Intracellular free magnesium and intracellular pH determination by 3 IP

NMR spectroscopy in healthy volunteers after glucose or magnesium load. In:
Current research in magnesium, edited by M. Halpem and J. Durlach. London:
John Libbey and Company, 1996, p. 19-20.

126.

Seelig, M. Cardiovascular consequences of magnesium deficiency and loss:

Pathogenesis, prevalence and manifestation- Magnesium and chloride loss in
refractory potassium repletion. Am J Cardiol 63: 4G-21G, 1989.

127.

Seelig, M. ISIS-4: Clinical controversy regarding magnesium infusion,

thrombolytic therapy, and acute myocardial infarction. Nutrition Reviews 53:
261-264, 1995.
128.

Seelig, M. Magnesium deficiency in the pathogenesis o f disease: Early roots

o f cardiovascular, skeletal, and renal abnormalities. New York: Plenum
Publishing Corp., 1980.
129.

Seelig, M., and R. Elin. Is there a place for magnesium in the treatment of acute

myocardial infarction? Am Heart J 132: 471-477, 1996.

B ib l io g r a p h y

Page 112

130.

Shechter, M., H. Hod, P. Chouraqui, E. Kaplinsky, and B. Rabinowitz.

Magnesium therapy in acute myocardial infarction when patients are not
candidates for thrombolytic therapy. Am J Cardiol 75: 321-323, 1995.

131.

Shechter, M., H. Hod, E. Kaplinsky, and B. Rabinowitz. The rationale of

magnesium as alternative therapy for patients with acute myocardial infarction
without thrombolytic therapy. Am Heart J 132: 483-486, 1996.

132.

Shechter, M., H. Hod, N. Marks, S. Behar, E. Kaplinsky, and B.
Rabinowitz. Beneficial effect of magnesium sulfate in acute myocardial

infarction. Am J Cardiol 66: 271-274, 1990.

133.

Sheehan, J. Importance of magnesium chloride repletion after myocardial

infarction. Am J Cardiol 63: 35G-38G, 1989.

134.

Shirey, T. Ionised magnesium: a new assay. Clinical Chemistry News 19:

12-13, 1993.

135.

Smetana, R. Cardiovascular medicine- the importance of magnesium in

coronary artery disease and acute myocardial infarction. In: Magnesium and
cardiovascular medicine, edited by R. Smetana. London: John Libbey and
Company Ltd, 1997, p. 5-11.

136.

Sperelakis, N., N. Tohse, and Y. Ohya. Excitation-contraction coupling in

skeletal, cardiac, and smooth muscle, edited by GB Frank, C. Paul Bianchi and
HEDJ ter Keurs New York: Plenum Press, 1992.

137.

Steurer, G., P. Yang, V. Rao, W. Mohl, D. Glogar, and R. Smetana. Acute

myocardial infarction, reperfusion injury, and intravenous magnesium therapy:
Basic concepts and clinical implications. Am Heart J 132: 478-482, 1996.

B ib l io g r a p h y

Page 113

138.

Teo, K., S. Yusuf, R. Collins, P. Held, and R. Peto. Effects of intravenous

magnesium in suspected acute myocardial infarction: overview of randomised
trials. Br Med J 303: 1499-1503, 1991.

139.

Tietz, N. The predictive value of laboratory tests. In: Textbook o f Clinical

Chemistry WB Saunders and Company, 1986.

140.

Timmiss, A. Early diagnosis of acute myocardial infarction. Br Med J 301:

941-942, 1990.

141.

Toffaletti, J. Practical review of ionised calcium and magnesium measurements

in clinical monitoring. LabMedica International: 25-28, 1992.

142.

Tsung, J., and S. Tsung. Creatine kinase isoenzymes in extracts of various

human skeletal muscles. Clin Chem 32: 1568-1570, 1986.

143.

Turi, Z., J. Rutherford, R. Roberts, J. Muller, A. Jaffe, R. Rude, C. Parker,
D. Raabe, P. Stone, T. Hartwell, S. Lewis, R. Parkey, H. Gold, T.
Robertson, B. Sobel, J. Willerson, and E. Braunwald. Electrocardiographic,

enzymatic and scintigraphic criteria of acute myocardial infarction as
determined from study of 726 patients (a Milis Study). Am J Cardiol 55:
1463-1468, 1985.

144.

Turlapaty, P., and B. Altura. Magnesium deficiency produces spasms of

coronary arteries: Relationship to etiology of sudden death ischemic heart
disease. Science 208: 198-200, 1980.

145.

Viallet, P., B. Morelle, J. Vigo, and J. Salmon. A comprehensive

determination of the intracellular concentration of magnesium ions in living cells
using microfluorometric techniques. In: Current research in magnesium, edited
by M. Halpem and J. Durlach. London: John Libbey and Company Ltd, 1996,
p. 15-17.
B ib l io g r a p h y

Page 114

146.

Vigorito, C., A. Giordano, P. Ferraro, P. Supino, M. De Pasquale, B.
Giordano, F. Lionetti, and F. Rengo. Reduction of pacing-induced myocardial

ischemia by intravenous magnesium sulfate. Am J Cardiol 75: 280-282, 1995.

147.

Wagner, G., C. Roe, L. Limbird, R. Rosati, and A. Wallace. The importance

of identification of the myocardial-specific isoenzyme of creatine phosphokinase
(MB form) in the diagnosis of acute myocardial infarction. Circulation 47:
263-269, 1973.

148.

Weiss, M., and B. Lasserre. Should magnesium therapy be considered for the

treatment of coronary heart disease? I. A critical appraisal of current facts and
hypotheses. Magnesium Research 7: 135-144, 1994.

149.

Wester, P. Electrolyte balance in heart failure and the role for magnesium ions.

Am J Cardiol 70: 44C-49C, 1992.

150.

Whang, R. Magnesium and potassium interrelationships in cardiac arrhythmias.

In: Magnesium in health and disease, edited by Y. Itokawa and J. Durlach.
London: John Libbey and Company Ltd, 1989, p. 209-217.

151.

Whang, R. Magnesium deficiency: pathogenesis, prevalence, and clinical

implications. Am J Med 82: 24-29, 1987.

152.

White, R., and H. Hartzell. Effects of intracellular free magnesium on calcium

current in isolated cardiac myocytes. Science 239: 778-780, 1988.

153.

Woods, K., and S. Fletcher. Long-term outcome after intravenous magnesium

sulphate in suspected acute myocardial infarction: the second Leicester
Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 343: 816-819,
1994.

B ib l io g r a p h y

Page 115

154.

Woods, K., S. Fletcher, C. Roffe, and Y. Haider. Intravenous magnesium

sulphate in suspected acute myocardial infarction: results of the second Leicester
Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 339: 1553-1558,
1992.

155.

World Health Organization. Report of the Joint International Society and

Federation

of Cardiology/World Health Organization Task Force

Standardization of Clinical Nomenclature.

on

Nomenclature and criteria for

diagnosis of ischemic heart disease. Circulation 59: 607-609, 1979.

156.

Wu, A., Y. Feng, and J. Contois. Prognostic value of cardiac troponin I in

patients with chest pain. Clin Chem 42: 651-652, 1996.

157.

Zoppi, F., A. De Gasperi, E. Guagnellini, A. Marocchi, E. Mineo, F.
Pazzucconi, C. Rossi, and D. Turrini. Performance of the AVL 988-4 analyser

in clinical determinations of ionised magnesium. In: Advances in magnesium
research: 1 Magnesium in cardiology, edited by R. Smetana. London: John
Libbey and Company Ltd, 1997, p. 553-569.

B ib l io g r a p h y

Page 116

